Interleukin Bispecific Antibody and Its Application
By developing a high-affinity bispecific antibody and modifying the Fc domain, the problem of short half-life of existing IL-1α and IL-1β inhibitors has been solved, achieving effective blocking and prolonging of the half-life of IL-1α and IL-1β, thus enhancing the therapeutic effect.
Patent Information
- Application Number
- CN202610676934.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2026-05-12
- Filing Date
- 2026-05-15
- Publication Date
- 2026-11-17
AI Technical Summary
Existing IL-1α and IL-1β inhibitors, such as anaspirin and linacept, have short half-lives, limited administration convenience, and are difficult to effectively block downstream signaling pathways of IL-1α and IL-1β.
A high-affinity bispecific antibody was developed that can specifically bind to IL-1α and IL-1β. By modifying the Fc domain to form a Knob-into-Hole (KIH) structure, the stability and half-life of the antibody were improved, heavy chain mismatch was reduced, and its durable effect in vivo was enhanced.
It effectively blocked IL-1α and IL-1β, prolonged their half-life in vivo, improved therapeutic efficacy, and enhanced the inhibitory ability on downstream signaling pathways of IL-1α and IL-1β.
Smart Images

Figure CN123106914A_ABST
Abstract
Description
[0001] This application claims the benefits of Chinese application No. 202510637079.7, filed on May 16, 2025; Chinese application No. 202610178606.7, filed on February 6, 2026; Chinese application No. 202610289450.X, filed on March 10, 2026; and Chinese application No. 202610652217.3, filed on May 12, 2026; the entire text of which is incorporated herein by reference. Technical Field
[0002] This invention belongs to the field of antibody drugs, specifically relating to bispecific antibodies that specifically bind to IL-1α and IL-1β. Furthermore, this invention also relates to pharmaceutical compositions comprising said bispecific antibodies, and related uses. Based on this, this invention also relates to the therapeutic uses of these bispecific antibodies. Background Technology
[0003] IL-1 is a core regulator of the immune system, playing an important role in the initiation of inflammation, immune regulation, and disease progression.
[0004] As key mediators of the innate immune response, IL-1α and IL-1β activate the NF-κB and MAPK pathways by binding to the IL-1 receptor (IL-1R1), rapidly activating the inflammatory response, inducing fever, vasodilation, and leukocyte chemotaxis, and promoting the migration of immune cells to sites of infection or injury. They also stimulate endothelial cells to express adhesion molecules (such as ICAM-1, Intercellular Cell Adhesion Molecule-1), accelerating leukocyte exudation; and promote the release of other pro-inflammatory factors (such as IL-6 and TNF-α) and chemokines (such as IL-8), forming an inflammatory cascade. Furthermore, IL-1 acts as a bridge between innate and adaptive immunity. It can activate dendritic cells, enhance antigen presentation, promote T cell (especially Th17 cells) differentiation, participate in B cell proliferation and antibody production, and regulate humoral immune responses.
[0005] IL-1α is constitutively expressed by epithelial cells, endothelial cells, and fibroblasts. It is released as an "alarm" during cell damage or necrosis, primarily participating in local inflammation and tissue repair. Its precursor form (pro-IL-1α) can bind to receptors and activate downstream signaling. IL-1β is mainly produced by activated immune cells (monocytes, macrophages, dendritic cells), and can also be produced by neutrophils and B cells under specific conditions. IL-1β production depends on the activation of inflammasomes (such as the NLRP3 inflammasome), which cleaves the precursor (pro-IL-1β) with caspase-1 to generate the mature form, which dominates systemic inflammation.
[0006] IL-1 plays a crucial role in a variety of diseases. Several rare inflammatory diseases, such as systemic juvenile idiopathic arthritis (sJIA), adult onsetstill disease (AOSD), cryopyrin-associated periodic syndromes (CAPS), familial Mediterranean fever (FMF), and tumor necrosis factor receptor 1 associated periodic syndrome (TRAPS), are caused by abnormal IL-1 signaling due to gene mutations in different sites. Studies have shown that blocking the IL-1 signaling pathway has good therapeutic effects. Analysis of various animal models and / or patient samples suggests that IL-1 plays an important role in inflammatory bowel disease, neurodegenerative diseases, metabolic diseases, aging, and tumors. In conclusion, targeting the IL-1 pathway has become an important therapeutic strategy for many inflammatory diseases.
[0007] Anakinra, an IL-1 pathway inhibitor, has been approved for CAPS, rheumatoid arthritis (RA), gout, familial Mediterranean fever, periodic fever syndrome, and neonatal multisystem inflammatory diseases. Rionacept has been approved for CAPS and recurrent pericarditis, IL-1 receptor antagonist deficiency, Mueller-Ville syndrome, and familial cold urticaria.
[0008] The approved drugs anaspirin and linarcept can simultaneously block downstream signals induced by IL-1α and IL-1β, but their short half-lives limit the convenience of administration. Summary of the Invention
[0009] Based on in-depth research, the inventors of this application have developed a high-affinity bispecific antibody that can specifically bind to IL-1α and IL-1β. The bispecific antibody can specifically recognize and bind to IL-1α and IL-1β, and can downregulate or block the activity of IL-1α and IL-1β (e.g., can inhibit or block the activation of downstream signaling pathways induced by IL-1α and / or IL-1β, or inhibit or block the secretion of cytokines induced by IL-1α and / or IL-1β).
[0010] Furthermore, the inventors of this application have conducted a series of modification studies based on the aforementioned bispecific antibody, obtaining a series of bispecific antibody molecules with better drugability (e.g., better purity), easier purification, better physicochemical properties (e.g., better stability) and / or extended half-life.
[0011] 1. Bispecific antibodies
[0012] Therefore, in one aspect, this application provides a bispecific antibody comprising a first antigen-binding domain that specifically binds to IL-1α (interleukin-1α) and a second antigen-binding domain that specifically binds to IL-1β (interleukin-1β).
[0013] The first antigen-binding domain includes a first light chain variable region (VL) and a first heavy chain variable region (VH), wherein the first VL and the first VH together form a domain that can specifically bind IL-1α; the second antigen-binding domain includes a second VL and a second VH, wherein the second VL and the second VH together form a domain that can specifically bind IL-1β.
[0014] Furthermore, the second VL includes LCDR1, LCDR2, and LCDR3 contained in the VL shown in any one of SEQ ID NO: 2-6, 10, 154-156; and / or, the second VH includes HCDR1, HCDR2, and HCDR3 contained in the VH shown in SEQ ID NO: 1 or 9. In some embodiments, the CDRs are defined according to the IMGT, Kabat, AbM, or Chothia numbering system.
[0015] In some implementations,
[0016] (a) The second VL comprises: LCDR1 comprising the sequence shown in SEQ ID NO: 16 or 17, LCDR2 comprising the sequence shown in SEQ ID NO: 18, and LCDR3 comprising the sequence shown in SEQ ID NO: 19;
[0017] And / or,
[0018] (b) The second VH comprises: HCDR1 comprising the sequence shown in SEQ ID NO: 13, HCDR2 comprising the sequence shown in SEQ ID NO: 14, and HCDR3 comprising the sequence shown in SEQ ID NO: 15.
[0019] In some implementations, the CDR is defined according to the Kabat numbering system.
[0020] In some embodiments, the second VL comprises an amino acid sequence as shown in any one of SEQ ID NO: 2-6, 10, 154-156, and / or the second VH comprises an amino acid sequence as shown in SEQ ID NO: 1 or 9.
[0021] In some embodiments, the second VL contains an amino acid sequence as shown in any one of SEQ ID NO: 2-6, 154-156, and / or the second VH contains an amino acid sequence as shown in SEQ ID NO: 1; or, the second VL contains an amino acid sequence as shown in SEQ ID NO: 10, and / or the second VH contains an amino acid sequence as shown in SEQ ID NO: 9.
[0022] In some embodiments, the first VL includes LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 12; and / or, the first VH includes HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 11. In some embodiments, the CDRs are defined according to the IMGT, Kabat, AbM, or Chothia numbering system.
[0023] In some implementation schemes,
[0024] (a) The first VL comprises: LCDR1 comprising the sequence shown in SEQ ID NO: 23, LCDR2 comprising the sequence shown in SEQ ID NO: 24, and LCDR3 comprising the sequence shown in SEQ ID NO: 25;
[0025] And / or,
[0026] (b) The first VH comprises: HCDR1 comprising the sequence shown in SEQ ID NO: 20, HCDR2 comprising the sequence shown in SEQ ID NO: 21, and HCDR3 comprising the sequence shown in SEQ ID NO: 22.
[0027] In some implementations, the CDR is defined according to the Kabat numbering system.
[0028] In some embodiments, the first VL contains an amino acid sequence as shown in SEQ ID NO: 12, and / or the first VH contains an amino acid sequence as shown in SEQ ID NO: 11.
[0029] In some embodiments, the second VL includes LCDR1, LCDR2, and LCDR3 contained in the VL shown in any one of SEQ ID NO: 2-6, 10, 154-156; the second VH includes HCDR1, HCDR2, and HCDR3 contained in the VH shown in SEQ ID NO: 1 or 9; the first VL includes LCDR1, LCDR2, and LCDR3 contained in the VL shown in SEQ ID NO: 12; and the first VH includes HCDR1, HCDR2, and HCDR3 contained in the VH shown in SEQ ID NO: 11. In some embodiments, the CDRs are defined according to the IMGT, Kabat, AbM, or Chothia numbering system.
[0030] In some embodiments, the second VL comprises: LCDR1 comprising the sequence shown in SEQ ID NO: 16 or 17, LCDR2 comprising the sequence shown in SEQ ID NO: 18, and LCDR3 comprising the sequence shown in SEQ ID NO: 19; the second VH comprises: HCDR1 comprising the sequence shown in SEQ ID NO: 13, HCDR2 comprising the sequence shown in SEQ ID NO: 14, and HCDR3 comprising the sequence shown in SEQ ID NO: 15; the first VL comprises: LCDR1 comprising the sequence shown in SEQ ID NO: 23, LCDR2 comprising the sequence shown in SEQ ID NO: 24, and LCDR3 comprising the sequence shown in SEQ ID NO: 25; and the first VH comprises: HCDR1 comprising the sequence shown in SEQ ID NO: 20, HCDR2 comprising the sequence shown in SEQ ID NO: 21, and HCDR3 comprising the sequence shown in SEQ ID NO: 22. In some embodiments, the CDR is defined according to the Kabat numbering system.
[0031] In some embodiments, the second VL contains an amino acid sequence as shown in any one of SEQ ID NO: 2-6, 10, 154-156, and the second VH contains an amino acid sequence as shown in SEQ ID NO: 1 or 9; and the first VL contains an amino acid sequence as shown in SEQ ID NO: 12, and the first VH contains an amino acid sequence as shown in SEQ ID NO: 11.
[0032] 1.1 Knob-into-Hole (KIH) Structure
[0033] In some embodiments, the bispecific antibody further comprises an Fc domain comprising first and second Fc domain monomers, and each of the first and second Fc domain monomers independently comprises a modification of one or more amino acids that promotes heterodimerization of the first and second Fc domain monomers.
[0034] In some embodiments, the Fc domain comprises a first Fc domain monomer containing amino acid modifications capable of forming a knot structure (e.g., substitution mutations T366W and / or S354C) and a second Fc domain monomer containing amino acid modifications capable of forming a hole structure (e.g., substitution mutations Y349C, T366S, L368A and / or Y407V), wherein the hole structure can pair with the knot structure to form a heterodimeric Fc domain.
[0035] Those skilled in the art will readily understand that the hole structure can pair with the knot structure to form a "knobin hole structure," which can be used to reduce heavy chain mismatches in bispecific antibodies. The "knob" and "hole" structures can be introduced by mutating corresponding positions in the CH3 domains of the two Fc domain monomers, thereby forming a specific interaction interface between the two Fc domain monomers (see Ridgway et al., Protein Eng., 9: 617-621 (1996); WO2006 / 028936; the entire text of which is incorporated herein by reference). Amino acid substitutions that can be used to form the "knob" structure include, but are not limited to, S354C and T366W, numbered according to the Eu numbering scheme. Amino acid substitutions that can be used to form the "hole" structure include, but are not limited to, Y349C, T366S, L368A, and Y407V, numbered according to the Eu numbering scheme. Due to the mutual attraction between the "knob" and "hole" structures, as well as the mutual repulsion between the "knob" and "knob" structures, the "knob in hole" structure can effectively reduce heavy chain mismatches in bispecific antibodies.
[0036] In some embodiments, the Fc domain monomer is derived from the Fc domain of a human immunoglobulin and includes modifications capable of forming a knock or hole structure. In some embodiments, the human immunoglobulin is IgG1, IgG2, IgG3, or IgG4. In some embodiments, the Fc domain monomer includes one or more modifications forming a knock structure, wherein the one or more modifications include S354C and / or T366W amino acid substitutions, wherein the numbering follows the Eu numbering scheme. In some embodiments, the Fc domain monomer includes S354C and T366W amino acid substitutions, wherein the numbering follows the Eu numbering scheme. In some embodiments, the Fc domain monomer includes one or more modifications forming a hole structure, wherein the one or more modifications include Y349C, T366S, L368A, and / or Y407V amino acid substitutions, wherein the numbering follows the Eu numbering scheme. In some embodiments, the Fc domain monomer includes Y349C, T366S, L368A, and Y407V amino acid substitutions, wherein the numbering follows the Eu numbering scheme.
[0037] In some embodiments, the first antigen-binding domain and the second antigen-binding domain are each linked to one of the first and second Fc domain monomers.
[0038] In some embodiments, the first antigen-binding domain is linked to the first Fc domain monomer, and the second antigen-binding domain is linked to the second Fc domain monomer; or, the first antigen-binding domain is linked to the second Fc domain monomer, and the second antigen-binding domain is linked to the first Fc domain monomer.
[0039] 1.1.1 Knob-into-Hole (KIH) Structure Fab-Fab
[0040] In some embodiments, the first antigen-binding domain and the second antigen-binding domain are Fab.
[0041] In some embodiments, the bispecific antibody comprises peptide chain IA, peptide chain IB, peptide chain IC, and peptide chain ID; wherein, peptide chain IA comprises: a first VH, a first heavy chain CH1 region, a first hinge region, and a first Fc domain monomer (or a second Fc domain monomer); peptide chain IB comprises: a second VH, a second heavy chain CH1 region, a second hinge region, and a second Fc domain monomer (or a first Fc domain monomer); peptide chain IC comprises: a first VL and a first light chain constant region; and peptide chain ID comprises: a second VL and a second light chain constant region.
[0042] In some embodiments, the peptide chain IA, from N-terminus to C-terminus, sequentially comprises: the first VH, the first heavy chain CH1 region, the first hinge region, and the first Fc domain monomer (or the second Fc domain monomer); the peptide chain IB, from N-terminus to C-terminus, sequentially comprises: the second VH, the second heavy chain CH1 region, the second hinge region, and the second Fc domain monomer (or the first Fc domain monomer); the peptide chain IC, from N-terminus to C-terminus, sequentially comprises: the first VL and the first light chain constant region; and the peptide chain ID, from N-terminus to C-terminus, sequentially comprises: the second VL and the second light chain constant region.
[0043] In some embodiments, adjacent domains of peptide chain IA are optionally connected by or without a connector, adjacent domains of peptide chain IB are optionally connected by or without a connector, adjacent domains of peptide chain IC are optionally connected by or without a connector, and / or adjacent domains of peptide chain ID are optionally connected by or without a connector.
[0044] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0045] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0046] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0047] In some embodiments, the first Fc domain monomer and / or the second Fc domain monomer are derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0048] In some embodiments, the first Fc domain monomer and / or the second Fc domain monomer have altered effector functions (enhanced or reduced or eliminated ADCC, CDC and / or ADCP activities) and / or prolonged half-lives (e.g., enhanced FcRn binding activity) compared to the wild-type Fc domain monomer from which they are derived.
[0049] In some embodiments, the first Fc domain monomer and / or the second Fc domain monomer are derived from human immunoglobulin IgG1; wherein, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer contains amino acid modifications capable of forming a knob structure (e.g., substitution mutations T366W and / or S354C), and the second Fc domain monomer contains amino acid modifications capable of forming a hole structure (e.g., substitution mutations Y349C, T366S, L368A and / or Y407V).
[0050] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer and / or the second Fc domain monomer each independently further comprise an amino acid mutation selected from:
[0051] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0052] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer and / or the second Fc domain monomer each independently further comprise an amino acid mutation selected from:
[0053] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0054] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer and / or the second Fc domain monomer each independently further comprise an amino acid mutation selected from:
[0055] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) T250Q, M428L and N434A, (vi) T307A, M428L and N434S, (vii) combinations of (i) and (iv) to (vi), (viii) combinations of (ii) and (vi) to (xi), (ix) combinations of (iii) and (iv) to (vi).
[0056] In some embodiments, one of the first Fc domain monomer and the second Fc domain monomer further comprises the amino acid mutations H435R and / or Y436F.
[0057] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0058] In some embodiments, the first Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 95, 111, 113, 116, 118, 120, 122, 124, 126, 128, 130-131, 134, and the second Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 94, 110, 112, 114-115, 117, 119, 121, 123, 125, 127, 129, 132, 135.
[0059] In some embodiments, the first Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 111, 113, 116, 118, 120, 122, 124, 126, 128, 130-131, 134, and the second Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 110, 112, 114-115, 117, 119, 121, 123, 125, 127, 129, 132, 135.
[0060] In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 111, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 110. In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 113, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 112. In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 111, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 114. In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 116, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 115. In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 134, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 117. In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 118, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 135. In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 120, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 119. In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 122, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 121. In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 124, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 123. In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 126, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 125. In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 128, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 127. In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 130, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 129.In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 131, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 112. In some embodiments, the first Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 111, and the second Fc domain monomer comprises the amino acid sequence shown in SEQ ID NO: 132.
[0061] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0062] (1) The first light chain constant region and the second light chain constant region are the same or different;
[0063] (2) The first light chain constant region and the second light chain constant region are each independently selected from the λ or κ light chain constant region of human immunoglobulin;
[0064] (3) The first light chain constant region and the second light chain constant region each independently contain an amino acid sequence as shown in any one of SEQ ID NO: 138-141 and 162;
[0065] (4) The CH1 region of the first heavy chain and the CH1 region of the second heavy chain are the same or different;
[0066] (5) The first heavy chain CH1 region and the second heavy chain CH1 region are each independently selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0067] (6) The first heavy chain CH1 region and the second heavy chain CH1 region each independently contain an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0068] (7) The first hinge area and the second hinge area are the same or different;
[0069] (8) The first hinge region and the second hinge region are each independently selected from hinge regions derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0070] (9) The first hinge region and the second hinge region each independently contain an amino acid sequence as shown in SEQ ID NO: 142.
[0071] In some embodiments, peptide chain IA comprises an amino acid sequence as shown in SEQ ID NO: 66, peptide chain IB comprises an amino acid sequence as shown in SEQ ID NO: 67, peptide chain IC comprises an amino acid sequence as shown in SEQ ID NO: 63, and / or peptide chain ID comprises an amino acid sequence as shown in SEQ ID NO: 68.
[0072] In some embodiments, peptide chain IA comprises an amino acid sequence as shown in SEQ ID NO: 69, peptide chain IB comprises an amino acid sequence as shown in SEQ ID NO: 70, peptide chain IC comprises an amino acid sequence as shown in SEQ ID NO: 63, and / or peptide chain ID comprises an amino acid sequence as shown in SEQ ID NO: 68.
[0073] In some embodiments, peptide chain IA comprises an amino acid sequence as shown in SEQ ID NO: 71, peptide chain IB comprises an amino acid sequence as shown in SEQ ID NO: 67, peptide chain IC comprises an amino acid sequence as shown in SEQ ID NO: 63, and / or peptide chain ID comprises an amino acid sequence as shown in SEQ ID NO: 72.
[0074] In some embodiments, peptide chain IA comprises an amino acid sequence as shown in SEQ ID NO: 73, peptide chain IB comprises an amino acid sequence as shown in SEQ ID NO: 74, peptide chain IC comprises an amino acid sequence as shown in SEQ ID NO: 63, and / or peptide chain ID comprises an amino acid sequence as shown in SEQ ID NO: 72.
[0075] In some embodiments, peptide chain IA comprises an amino acid sequence as shown in SEQ ID NO: 75, peptide chain IB comprises an amino acid sequence as shown in SEQ ID NO: 76, peptide chain IC comprises an amino acid sequence as shown in SEQ ID NO: 63, and / or peptide chain ID comprises an amino acid sequence as shown in SEQ ID NO: 72.
[0076] In some embodiments, peptide chain IA comprises an amino acid sequence as shown in SEQ ID NO: 77, peptide chain IB comprises an amino acid sequence as shown in SEQ ID NO: 78, peptide chain IC comprises an amino acid sequence as shown in SEQ ID NO: 63, and / or peptide chain ID comprises an amino acid sequence as shown in SEQ ID NO: 72.
[0077] In some embodiments, peptide chain IA comprises an amino acid sequence as shown in SEQ ID NO: 79, peptide chain IB comprises an amino acid sequence as shown in SEQ ID NO: 80, peptide chain IC comprises an amino acid sequence as shown in SEQ ID NO: 63, and / or peptide chain ID comprises an amino acid sequence as shown in SEQ ID NO: 72.
[0078] In some embodiments, peptide chain IA comprises an amino acid sequence as shown in SEQ ID NO: 81, peptide chain IB comprises an amino acid sequence as shown in SEQ ID NO: 70, peptide chain IC comprises an amino acid sequence as shown in SEQ ID NO: 63, and / or peptide chain ID comprises an amino acid sequence as shown in SEQ ID NO: 72.
[0079] In some embodiments, peptide chain IA comprises an amino acid sequence as shown in SEQ ID NO: 82, peptide chain IB comprises an amino acid sequence as shown in SEQ ID NO: 83, peptide chain IC comprises an amino acid sequence as shown in SEQ ID NO: 63, and / or peptide chain ID comprises an amino acid sequence as shown in SEQ ID NO: 72.
[0080] In some embodiments, peptide chain IA comprises an amino acid sequence as shown in SEQ ID NO: 84, peptide chain IB comprises an amino acid sequence as shown in SEQ ID NO: 85, peptide chain IC comprises an amino acid sequence as shown in SEQ ID NO: 63, and / or peptide chain ID comprises an amino acid sequence as shown in SEQ ID NO: 72.
[0081] In some embodiments, peptide chain IA comprises an amino acid sequence as shown in SEQ ID NO: 86, peptide chain IB comprises an amino acid sequence as shown in SEQ ID NO: 87, peptide chain IC comprises an amino acid sequence as shown in SEQ ID NO: 63, and / or peptide chain ID comprises an amino acid sequence as shown in SEQ ID NO: 72.
[0082] In some embodiments, peptide chain IA comprises an amino acid sequence as shown in SEQ ID NO: 88, peptide chain IB comprises an amino acid sequence as shown in SEQ ID NO: 89, peptide chain IC comprises an amino acid sequence as shown in SEQ ID NO: 63, and / or peptide chain ID comprises an amino acid sequence as shown in SEQ ID NO: 72.
[0083] In some embodiments, peptide chain IA comprises an amino acid sequence as shown in SEQ ID NO: 69, peptide chain IB comprises an amino acid sequence as shown in SEQ ID NO: 60, peptide chain IC comprises an amino acid sequence as shown in SEQ ID NO: 63, and / or peptide chain ID comprises an amino acid sequence as shown in SEQ ID NO: 72.
[0084] 1.1.2 Knob-into-Hole (KIH) Structure Fab-Fab (CrossMab)
[0085] In some embodiments, the first antigen-binding domain and the second antigen-binding domain are Fabs, and the Fab of the first antigen-binding domain or the second antigen-binding domain contains domain exchanges of the form of CrossMab.
[0086] In some implementations, the CrossMab-form domain exchange is selected from:
[0087] (i) CrossMab Fab: In the Fab, the antibody light chain CL-VL and the antibody heavy chain CH1-VH are exchanged;
[0088] (ii) CrossMab VH-VL: In the Fab, the VL and VH of the antibody are exchanged;
[0089] (iii) CrossMab CH1-CL: In the Fab, the CH and CL of the antibody are exchanged.
[0090] CrossMab is a method for preventing light chain and heavy chain mismatch, see US Patent US9266967B2, the entire text of which is incorporated herein by reference. This method primarily utilizes the principle of mutual repulsion between identical parts of the antibody, i.e., VH repulses VH, CH1 repulses CH1, CL repulses CL, and VL repulses VL. It prevents light chain mismatch by exchanging regions of the heavy and light chains within one Fab of a bispecific antibody (e.g., exchanging light chain CL-VL with heavy chain CH1-VH, VL and VH, or CH and CL).
[0091] In some embodiments, the Fab of the second antigen-binding domain contains domain exchanges of the form of CrossMab.
[0092] In some embodiments, the bispecific antibody comprises peptide chain II-A, peptide chain II-B, peptide chain II-C, and peptide chain II-D; wherein, peptide chain II-A comprises: a second VL, a first heavy chain CH1 region, a first hinge region, and a first Fc domain monomer (or a second Fc domain monomer); peptide chain II-B comprises: a first VH, a second heavy chain CH1 region, a second hinge region, and a second Fc domain monomer (or a first Fc domain monomer); peptide chain II-C comprises: a second VH and a first light chain constant region; and peptide chain II-D comprises: a first VL and a second light chain constant region.
[0093] In some embodiments, peptide chain II-A comprises, from N-terminus to C-terminus, the following sequentially: the second VL, the first heavy chain CH1 region, the first hinge region, and the first Fc domain monomer (or the second Fc domain monomer); peptide chain II-B comprises, from N-terminus to C-terminus, the following sequentially: the first VH, the second heavy chain CH1 region, the second hinge region, and the second Fc domain monomer (or the first Fc domain monomer); peptide chain II-C comprises, from N-terminus to C-terminus, the following sequentially: the second VH and the first light chain constant region; and peptide chain II-D comprises, from N-terminus to C-terminus, the following sequentially: the first VL and the second light chain constant region.
[0094] In some embodiments, adjacent domains of peptide chain II-A are optionally connected by or without a linker, adjacent domains of peptide chain II-B are optionally connected by or without a linker, adjacent domains of peptide chain II-C are optionally connected by or without a linker, and / or adjacent domains of peptide chain II-D are optionally connected by or without a linker.
[0095] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0096] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0097] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0098] In some embodiments, the first Fc domain monomer and / or the second Fc domain monomer are derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0099] In some embodiments, the first Fc domain monomer and / or the second Fc domain monomer have altered effector functions (enhanced or reduced or eliminated ADCC, CDC and / or ADCP activities) and / or prolonged half-lives (e.g., enhanced FcRn binding activity) compared to the wild-type Fc domain monomer from which they are derived.
[0100] In some embodiments, the first Fc domain monomer and / or the second Fc domain monomer are derived from human immunoglobulin IgG1; wherein, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer contains amino acid modifications capable of forming a knob structure (e.g., substitution mutations T366W and / or S354C), and the second Fc domain monomer contains amino acid modifications capable of forming a hole structure (e.g., substitution mutations Y349C, T366S, L368A and / or Y407V).
[0101] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer and / or the second Fc domain monomer each independently further comprise an amino acid mutation selected from:
[0102] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0103] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer and / or the second Fc domain monomer each independently further comprise an amino acid mutation selected from:
[0104] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0105] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer and / or the second Fc domain monomer each independently further comprise an amino acid mutation selected from:
[0106] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) T250Q, M428L and N434A, (vi) T307A, M428L and N434S, (vii) combinations of (i) and (iv) to (vi), (viii) combinations of (ii) and (vi) to (xi), (ix) combinations of (iii) and (iv) to (vi).
[0107] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0108] In some embodiments, the first Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 95, 111, 113, 116, 118, 120, 122, 124, 126, 128, 130-131, 134, and the second Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 94, 110, 112, 114-115, 117, 119, 121, 123, 125, 127, 129, 132, 135. In some embodiments, the first Fc domain monomer comprises an amino acid sequence as shown in SEQ ID NO: 95, and the second Fc domain monomer comprises an amino acid sequence as shown in SEQ ID NO: 94.
[0109] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0110] (1) The first light chain constant region and the second light chain constant region are the same or different;
[0111] (2) The first light chain constant region and the second light chain constant region are each independently selected from the λ or κ light chain constant region of human immunoglobulin;
[0112] (3) The first light chain constant region and the second light chain constant region each independently contain an amino acid sequence as shown in any one of SEQ ID NO: 138-141 and 162;
[0113] (4) The CH1 region of the first heavy chain and the CH1 region of the second heavy chain are the same or different;
[0114] (5) The first heavy chain CH1 region and the second heavy chain CH1 region are each independently selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0115] (6) The first heavy chain CH1 region and the second heavy chain CH1 region each independently contain an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0116] (7) The first hinge area and the second hinge area are the same or different;
[0117] (8) The first hinge region and the second hinge region are each independently selected from hinge regions derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0118] (9) The first hinge region and the second hinge region each independently contain an amino acid sequence as shown in SEQ ID NO: 142.
[0119] In some embodiments, peptide chain II-A comprises the amino acid sequence shown in SEQ ID NO: 26, peptide chain II-B comprises the amino acid sequence shown in SEQ ID NO: 27, peptide chain II-C comprises the amino acid sequence shown in SEQ ID NO: 28, and / or peptide chain II-D comprises the amino acid sequence shown in SEQ ID NO: 29.
[0120] 1.1.3 Knob-into-Hole (KIH) Structure Fab (CrossMab)-Fab
[0121] In some embodiments, the Fab of the first antigen-binding domain contains domain exchanges of the form of CrossMab.
[0122] In some embodiments, the bispecific antibody comprises peptide chain II-A, peptide chain II-B, peptide chain II-C, and peptide chain II-D; wherein, peptide chain II-A comprises a second VH, a first heavy chain CH1 region, a first hinge region, and a first Fc domain monomer (or a second Fc domain monomer); peptide chain II-B comprises a first VL, a second heavy chain CH1 region, a second hinge region, and a second Fc domain monomer (or a first Fc domain monomer); peptide chain II-C comprises a second VL and a first light chain constant region; and peptide chain II-D comprises a first VH and a second light chain constant region.
[0123] In some embodiments, peptide chain II-A comprises, from N-terminus to C-terminus, the following sequentially: the second VH, the first heavy chain CH1 region, the first hinge region, and the first Fc domain monomer (or the second Fc domain monomer); peptide chain II-B comprises, from N-terminus to C-terminus, the following sequentially: the first VL, the second heavy chain CH1 region, the second hinge region, and the second Fc domain monomer (or the first Fc domain monomer); peptide chain II-C comprises, from N-terminus to C-terminus, the following sequentially: the second VL and the first light chain constant region; and peptide chain II-D comprises, from N-terminus to C-terminus, the following sequentially: the first VH and the second light chain constant region.
[0124] In some embodiments, adjacent domains of peptide chain II-A are optionally connected by or without a linker, adjacent domains of peptide chain II-B are optionally connected by or without a linker, adjacent domains of peptide chain II-C are optionally connected by or without a linker, and / or adjacent domains of peptide chain II-D are optionally connected by or without a linker.
[0125] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0126] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0127] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0128] In some embodiments, the first Fc domain monomer and / or the second Fc domain monomer are derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0129] In some embodiments, the first Fc domain monomer and / or the second Fc domain monomer have altered effector functions (enhanced or reduced or eliminated ADCC, CDC and / or ADCP activities) and / or prolonged half-lives (e.g., enhanced FcRn binding activity) compared to the wild-type Fc domain monomer from which they are derived.
[0130] In some embodiments, the first Fc domain monomer and / or the second Fc domain monomer are derived from human immunoglobulin IgG1; wherein, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer contains amino acid modifications capable of forming a knob structure (e.g., substitution mutations T366W and / or S354C), and the second Fc domain monomer contains amino acid modifications capable of forming a hole structure (e.g., substitution mutations Y349C, T366S, L368A and / or Y407V).
[0131] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer and / or the second Fc domain monomer each independently further comprise an amino acid mutation selected from:
[0132] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0133] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer and / or the second Fc domain monomer each independently further comprise an amino acid mutation selected from:
[0134] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0135] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer and / or the second Fc domain monomer each independently further comprise an amino acid mutation selected from:
[0136] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) T250Q, M428L and N434A, (vi) T307A, M428L and N434S, (vii) combinations of (i) and (iv) to (vi), (viii) combinations of (ii) and (vi) to (xi), (ix) combinations of (iii) and (iv) to (vi).
[0137] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0138] In some embodiments, the first Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 95, 111, 113, 116, 118, 120, 122, 124, 126, 128, 130-131, 134, and the second Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 94, 110, 112, 114-115, 117, 119, 121, 123, 125, 127, 129, 132, 135. In some embodiments, the first Fc domain monomer comprises an amino acid sequence as shown in SEQ ID NO: 95, and the second Fc domain monomer comprises an amino acid sequence as shown in SEQ ID NO: 94.
[0139] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0140] (1) The first light chain constant region and the second light chain constant region are the same or different;
[0141] (2) The first light chain constant region and the second light chain constant region are each independently selected from the λ or κ light chain constant region of human immunoglobulin;
[0142] (3) The first light chain constant region and the second light chain constant region each independently contain an amino acid sequence as shown in any one of SEQ ID NO: 138-141 and 162;
[0143] (4) The CH1 region of the first heavy chain and the CH1 region of the second heavy chain are the same or different;
[0144] (5) The first heavy chain CH1 region and the second heavy chain CH1 region are each independently selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0145] (6) The first heavy chain CH1 region and the second heavy chain CH1 region each independently contain an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0146] (7) The first hinge area and the second hinge area are the same or different;
[0147] (8) The first hinge region and the second hinge region are each independently selected from hinge regions derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0148] (9) The first hinge region and the second hinge region each independently contain an amino acid sequence as shown in SEQ ID NO: 142.
[0149] In some embodiments, peptide chain II-A comprises an amino acid sequence as shown in SEQ ID NO: 159, peptide chain II-B comprises an amino acid sequence as shown in SEQ ID NO: 158, peptide chain II-C comprises an amino acid sequence as shown in SEQ ID NO: 161, and / or peptide chain II-D comprises an amino acid sequence as shown in SEQ ID NO: 160.
[0150] 1.2 Fab-Fab
[0151] In some embodiments, the first antigen-binding domain and the second antigen-binding domain are Fab.
[0152] 1.2.1 Fab-Fab (CrossMab)
[0153] In some embodiments, the Fab of the second antigen-binding domain contains domain exchanges of the form of CrossMab.
[0154] 1.2.1.1 Fab-Fab(CrossMab)-Configuration I
[0155] In some embodiments, the Fab of the second antigen-binding domain contains a domain exchange of the form of CrossMab VH-VL.
[0156] In some embodiments, the bispecific antibody comprises peptide chain III-A, peptide chain III-B, and peptide chain III-C; wherein, peptide chain III-A comprises a second VL, a first heavy chain CH1 region, a first VH, a second heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain III-B comprises the second VH and a first light chain constant region; and peptide chain III-C comprises the first VL and a second light chain constant region.
[0157] In some embodiments, peptide chain III-A comprises, from N-terminus to C-terminus, the following components in sequence: the second VL, the first heavy chain CH1 region, the first VH, the second heavy chain CH1 region, the hinge region, and the Fc domain monomer; peptide chain III-B comprises, from N-terminus to C-terminus, the second VH and the first light chain constant region; and peptide chain III-C comprises, from N-terminus to C-terminus, the first VL and the second light chain constant region.
[0158] In some embodiments, adjacent domains of peptide chain III-A are optionally connected by or without a linker, adjacent domains of peptide chain III-B are optionally connected by or without a linker, and / or adjacent domains of peptide chain III-C are optionally connected by or without a linker.
[0159] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0160] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0161] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0162] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0163] Those skilled in the art will readily understand that the Fc domain monomers derived from human immunoglobulins include both Fc domain monomers directly derived from human immunoglobulins and Fc domain monomers obtained by modifying or altering Fc domain monomers derived from human immunoglobulins.
[0164] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0165] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0166] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0167] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0168] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0169] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0170] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0171] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0172] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0173] (1) The first light chain constant region and the second light chain constant region are the same or different;
[0174] (2) The first light chain constant region and the second light chain constant region are each independently selected from the λ or κ light chain constant region of human immunoglobulin;
[0175] (3) The first light chain constant region and the second light chain constant region each independently contain an amino acid sequence as shown in any one of SEQ ID NO: 138-141 and 162;
[0176] (4) The CH1 region of the first heavy chain and the CH1 region of the second heavy chain are the same or different;
[0177] (5) The first heavy chain CH1 region and the second heavy chain CH1 region are each independently selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0178] (6) The first heavy chain CH1 region and the second heavy chain CH1 region each independently contain an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0179] (7) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0180] (8) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0181] In some embodiments, peptide chain III-A comprises an amino acid sequence as shown in SEQ ID NO: 32, peptide chain III-B comprises an amino acid sequence as shown in SEQ ID NO: 28, and / or peptide chain III-C comprises an amino acid sequence as shown in SEQ ID NO: 29.
[0182] In some embodiments, the bispecific antibody comprises two identical or different peptide chains III-A, two identical or different peptide chains III-B, and two identical or different peptide chains III-C.
[0183] In some embodiments, the bispecific antibody comprises two identical peptide chains III-A, two identical peptide chains III-B, and two identical peptide chains III-C.
[0184] 1.2.1.2 Fab-Fab(CrossMab)-Configuration II / FIT-Ig
[0185] In some embodiments, the Fab of the second antigen-binding domain contains domain exchanges in the form of CrossMab CH1-CL.
[0186] In some embodiments, the bispecific antibody comprises peptide chain III-A, peptide chain III-B, and peptide chain III-C; wherein, peptide chain III-A comprises a first VH, a first heavy chain CH1 region, a hinge region, an Fc domain monomer, a second VH, and a first light chain constant region; peptide chain III-B comprises a second VL and a second heavy chain CH1 region; and peptide chain III-C comprises a first VL and a second light chain constant region.
[0187] In some embodiments, peptide chain III-A comprises, from N-terminus to C-terminus, the following sequentially: a first VH, a first heavy chain CH1 region, a hinge region, an Fc domain monomer, a second VH, and a first light chain constant region; peptide chain III-B comprises, from N-terminus to C-terminus, the following sequentially: the second VL and the second heavy chain CH1 region; and peptide chain III-C comprises, from N-terminus to C-terminus, the following sequentially: the first VL and the second light chain constant region.
[0188] In some embodiments, adjacent domains of peptide chain III-A are optionally connected by or without a linker, adjacent domains of peptide chain III-B are optionally connected by or without a linker, and / or adjacent domains of peptide chain III-C are optionally connected by or without a linker.
[0189] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0190] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) nThe peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0191] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0192] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0193] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0194] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0195] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0196] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0197] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0198] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0199] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0200] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0201] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0202] (1) The first light chain constant region and the second light chain constant region are the same or different;
[0203] (2) The first light chain constant region and the second light chain constant region are each independently selected from the λ or κ light chain constant region of human immunoglobulin;
[0204] (3) The first light chain constant region and the second light chain constant region each independently contain an amino acid sequence as shown in any one of SEQ ID NO: 138-141 and 162;
[0205] (4) The CH1 region of the first heavy chain and the CH1 region of the second heavy chain are the same or different;
[0206] (5) The first heavy chain CH1 region and the second heavy chain CH1 region are each independently selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0207] (6) The first heavy chain CH1 region and the second heavy chain CH1 region each independently contain an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0208] (7) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0209] (8) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0210] In some embodiments, peptide chain III-A comprises an amino acid sequence as shown in SEQ ID NO: 33, peptide chain III-B comprises an amino acid sequence as shown in SEQ ID NO: 34, and / or peptide chain III-C comprises an amino acid sequence as shown in SEQ ID NO: 35.
[0211] In some embodiments, the bispecific antibody comprises two identical or different peptide chains III-A, two identical or different peptide chains III-B, and two identical or different peptide chains III-C.
[0212] In some embodiments, the bispecific antibody comprises two identical peptide chains III-A, two identical peptide chains III-B, and two identical peptide chains III-C.
[0213] Based on the disclosure of this application, those skilled in the art will readily understand that in the bispecific antibody described in section 1.2.1.2 of this application, the light chain of the second antigen-binding domain is optionally fused to the N-terminus of the heavy chain of the first antigen-binding domain via a linker, thus also possessing the typical bispecific antibody structural characteristics of the “FIT-Ig” (Fabs-In-Tandem Immunoglobulin) form.
[0214] As used herein, the “FIT-Ig” structure of bispecific antibodies has the meaning commonly understood by those skilled in the art. Generally speaking, bispecific antibodies employing the “FIT-Ig” structure typically include the following core features: by cross-linking the Fabs of different antigen-binding domains, a bispecific antibody molecule capable of simultaneously binding two different antigens (or epitopes) is formed.
[0215] 1.2.1.3 Fab-Fab(CrossMab)-Configuration III
[0216] In some embodiments, the Fab of the second antigen-binding domain contains domain exchanges of the form of CrossMab Fab.
[0217] In some embodiments, the bispecific antibody comprises peptide chain III-A, peptide chain III-B, and peptide chain III-C; wherein, peptide chain III-A comprises a second VL, a first light chain constant region, a first VH, a first heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain III-B comprises the second VH and a second heavy chain CH1 region; and peptide chain III-C comprises the first VL and a second light chain constant region.
[0218] In some embodiments, peptide chain III-A comprises, from N-terminus to C-terminus, the second VL, the first light chain constant region, the first VH, the first heavy chain CH1 region, the hinge region, and the Fc domain monomer; peptide chain III-B comprises, from N-terminus to C-terminus, the second VH and the second heavy chain CH1 region; and peptide chain III-C comprises, from N-terminus to C-terminus, the first VL and the second light chain constant region.
[0219] In some embodiments, adjacent domains of peptide chain III-A are optionally connected by or without a linker, adjacent domains of peptide chain III-B are optionally connected by or without a linker, and / or adjacent domains of peptide chain III-C are optionally connected by or without a linker.
[0220] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0221] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0222] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0223] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0224] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0225] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0226] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0227] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0228] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0229] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0230] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0231] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0232] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0233] (1) The first light chain constant region and the second light chain constant region are the same or different;
[0234] (2) The first light chain constant region and the second light chain constant region are each independently selected from the λ or κ light chain constant region of human immunoglobulin;
[0235] (3) The first light chain constant region and the second light chain constant region each independently contain an amino acid sequence as shown in any one of SEQ ID NO: 138-141 and 162;
[0236] (4) The CH1 region of the first heavy chain and the CH1 region of the second heavy chain are the same or different;
[0237] (5) The first heavy chain CH1 region and the second heavy chain CH1 region are each independently selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0238] (6) The first heavy chain CH1 region and the second heavy chain CH1 region each independently contain an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0239] (7) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0240] (8) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0241] In some embodiments, peptide chain III-A comprises an amino acid sequence as shown in SEQ ID NO: 40, peptide chain III-B comprises an amino acid sequence as shown in SEQ ID NO: 41, and / or peptide chain III-C comprises an amino acid sequence as shown in SEQ ID NO: 29.
[0242] In some embodiments, the bispecific antibody comprises two identical or different peptide chains III-A, two identical or different peptide chains III-B, and two identical or different peptide chains III-C.
[0243] In some embodiments, the bispecific antibody comprises two identical peptide chains III-A, two identical peptide chains III-B, and two identical peptide chains III-C.
[0244] 1.2.2 Fab (CrossMab) - Fab
[0245] In some embodiments, the Fab of the first antigen-binding domain contains domain exchanges of the form of CrossMab.
[0246] 1.2.2.1 Fab(CrossMab)-Fab-Configuration I
[0247] In some embodiments, the Fab of the first antigen-binding domain contains domain exchanges of the form of CrossMab VH-VL.
[0248] In some embodiments, the bispecific antibody comprises peptide chain III-A, peptide chain III-B, and peptide chain III-C; wherein, peptide chain III-A comprises a first VL, a first heavy chain CH1 region, a second VH, a second heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain III-B comprises the first VH and a first light chain constant region; and peptide chain III-C comprises the second VL and a second light chain constant region.
[0249] In some embodiments, peptide chain III-A comprises, from N-terminus to C-terminus, the first VL, the first heavy chain CH1 region, the second VH, the second heavy chain CH1 region, the hinge region, and the Fc domain monomer; peptide chain III-B comprises, from N-terminus to C-terminus, the first VH and the first light chain constant region; and peptide chain III-C comprises, from N-terminus to C-terminus, the second VL and the second light chain constant region.
[0250] In some embodiments, adjacent domains of peptide chain III-A are optionally connected by or without a linker, adjacent domains of peptide chain III-B are optionally connected by or without a linker, and / or adjacent domains of peptide chain III-C are optionally connected by or without a linker.
[0251] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0252] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0253] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0254] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0255] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0256] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0257] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0258] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0259] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0260] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0261] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0262] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0263] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0264] (1) The first light chain constant region and the second light chain constant region are the same or different;
[0265] (2) The first light chain constant region and the second light chain constant region are each independently selected from the λ or κ light chain constant region of human immunoglobulin;
[0266] (3) The first light chain constant region and the second light chain constant region each independently contain an amino acid sequence as shown in any one of SEQ ID NO: 138-141 and 162;
[0267] (4) The CH1 region of the first heavy chain and the CH1 region of the second heavy chain are the same or different;
[0268] (5) The first heavy chain CH1 region and the second heavy chain CH1 region are each independently selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0269] (6) The first heavy chain CH1 region and the second heavy chain CH1 region each independently contain an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0270] (7) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0271] (8) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0272] In some embodiments, the bispecific antibody comprises two identical or different peptide chains III-A, two identical or different peptide chains III-B, and two identical or different peptide chains III-C.
[0273] In some embodiments, the bispecific antibody comprises two identical peptide chains III-A, two identical peptide chains III-B, and two identical peptide chains III-C.
[0274] 1.2.2.2 Fab(CrossMab)-Fab-Configuration II / FIT-Ig
[0275] In some embodiments, the Fab of the first antigen-binding domain contains domain exchanges in the form of CrossMab CH1-CL.
[0276] In some embodiments, the bispecific antibody comprises peptide chain III-A, peptide chain III-B, and peptide chain III-C; wherein, peptide chain III-A comprises the second VH, a first heavy chain CH1 region, a hinge region, an Fc domain monomer, the first VH, and a first light chain constant region; peptide chain III-B comprises the first VL and the second heavy chain CH1 region; and peptide chain III-C comprises the second VL and the second light chain constant region.
[0277] In some embodiments, peptide chain III-A comprises, from N-terminus to C-terminus, the second VH, the first heavy chain CH1 region, the hinge region, the Fc domain monomer, the first VH, and the first light chain constant region; peptide chain III-B comprises, from N-terminus to C-terminus, the first VL and the second heavy chain CH1 region; and peptide chain III-C comprises, from N-terminus to C-terminus, the second VL and the second light chain constant region.
[0278] In some embodiments, adjacent domains of peptide chain III-A are optionally connected by or without a linker, adjacent domains of peptide chain III-B are optionally connected by or without a linker, and / or adjacent domains of peptide chain III-C are optionally connected by or without a linker.
[0279] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0280] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0281] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0282] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0283] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0284] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0285] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0286] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0287] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0288] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0289] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0290] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0291] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0292] (1) The first light chain constant region and the second light chain constant region are the same or different;
[0293] (2) The first light chain constant region and the second light chain constant region are each independently selected from the λ or κ light chain constant region of human immunoglobulin;
[0294] (3) The first light chain constant region and the second light chain constant region each independently contain an amino acid sequence as shown in any one of SEQ ID NO: 138-141 and 162;
[0295] (4) The CH1 region of the first heavy chain and the CH1 region of the second heavy chain are the same or different;
[0296] (5) The first heavy chain CH1 region and the second heavy chain CH1 region are each independently selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0297] (6) The first heavy chain CH1 region and the second heavy chain CH1 region each independently contain an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0298] (7) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0299] (8) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0300] In some embodiments, the bispecific antibody comprises two identical or different peptide chains III-A, two identical or different peptide chains III-B, and two identical or different peptide chains III-C.
[0301] In some embodiments, the bispecific antibody comprises two identical peptide chains III-A, two identical peptide chains III-B, and two identical peptide chains III-C.
[0302] Based on the disclosure of this application, those skilled in the art will readily understand that in the bispecific antibody described in section 1.2.2.2 of this application, the light chain of the first antigen-binding domain is optionally fused to the N-terminus of the heavy chain of the second antigen-binding domain via a linker, thus also possessing the typical bispecific antibody structural characteristics of the “FIT-Ig” (Fabs-In-Tandem Immunoglobulin) form.
[0303] 1.2.2.3 Fab(CrossMab)-Fab-Configuration III
[0304] In some implementations, the Fab of the first antigen-binding domain includes domain exchanges of the form of CrossMab Fab.
[0305] In some embodiments, the bispecific antibody comprises peptide chain III-A, peptide chain III-B, and peptide chain III-C; wherein, peptide chain III-A comprises a first VL, a first light chain constant region, a second VH, a first heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain III-B comprises the first VH and a second heavy chain CH1 region; and peptide chain III-C comprises the second VL and a second light chain constant region.
[0306] In some embodiments, peptide chain III-A comprises, from N-terminus to C-terminus, the first VL, the first light chain constant region, the second VH, the first heavy chain CH1 region, the hinge region, and the Fc domain monomer; peptide chain III-B comprises, from N-terminus to C-terminus, the first VH and the second heavy chain CH1 region; and peptide chain III-C comprises, from N-terminus to C-terminus, the second VL and the second light chain constant region.
[0307] In some embodiments, adjacent domains of peptide chain III-A are optionally connected by or without a linker, adjacent domains of peptide chain III-B are optionally connected by or without a linker, and / or adjacent domains of peptide chain III-C are optionally connected by or without a linker.
[0308] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0309] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0310] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0311] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0312] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0313] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0314] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0315] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0316] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0317] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0318] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0319] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0320] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0321] (1) The first light chain constant region and the second light chain constant region are the same or different;
[0322] (2) The first light chain constant region and the second light chain constant region are each independently selected from the λ or κ light chain constant region of human immunoglobulin;
[0323] (3) The first light chain constant region and the second light chain constant region each independently contain an amino acid sequence as shown in any one of SEQ ID NO: 138-141 and 162;
[0324] (4) The CH1 region of the first heavy chain and the CH1 region of the second heavy chain are the same or different;
[0325] (5) The first heavy chain CH1 region and the second heavy chain CH1 region are each independently selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0326] (6) The first heavy chain CH1 region and the second heavy chain CH1 region each independently contain an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0327] (7) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0328] (8) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0329] In some embodiments, the bispecific antibody comprises two identical or different peptide chains III-A, two identical or different peptide chains III-B, and two identical or different peptide chains III-C.
[0330] In some embodiments, the bispecific antibody comprises two identical peptide chains III-A, two identical peptide chains III-B, and two identical peptide chains III-C.
[0331] 1.3 Fab-scFv
[0332] In some embodiments, the second antigen-binding domain is scFv, and the first antigen-binding domain is Fab.
[0333] In some implementations, an intrachain disulfide bond can be formed between the second VH and the second VL.
[0334] In some embodiments, the second VL contains an amino acid sequence as shown in SEQ ID NO: 10, and the second VH contains an amino acid sequence as shown in SEQ ID NO: 9.
[0335] In some embodiments, the second VH and the second VL are connected by a peptide linker comprising the sequence shown in SEQ ID NO: 151.
[0336] 1.3.1 Fab-scFv-Configuration I
[0337] In some embodiments, the bispecific antibody comprises peptide chain IV-A and peptide chain IV-B; wherein, peptide chain IV-A comprises: a first VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; and peptide chain IV-B comprises: a first VL, a light chain constant region, a second VH, and a second VL.
[0338] In some embodiments, peptide chain IV-A comprises, from N-terminus to C-terminus, the following sequentially: the first VH, the heavy chain CH1 region, the hinge region, and the Fc domain monomer; peptide chain IV-B comprises, from N-terminus to C-terminus, the following sequentially: (i) the first VL, the light chain constant region, the second VH, and the second VL, or (ii) the first VL, the light chain constant region, the second VL, and the second VH.
[0339] In some embodiments, adjacent domains of peptide chain IV-A are optionally connected by or without a linker, and / or adjacent domains of peptide chain IV-B are optionally connected by or without a linker.
[0340] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0341] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0342] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0343] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0344] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0345] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0346] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0347] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0348] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0349] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0350] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0351] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0352] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0353] (1) The light chain constant region is selected from the λ or κ light chain constant region of human immunoglobulin;
[0354] (2) The light chain constant region contains an amino acid sequence as shown in any one of SEQ ID NO: 138-141 or 162;
[0355] (3) The heavy chain CH1 region is selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0356] (4) The heavy chain CH1 region contains an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0357] (5) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0358] (6) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0359] In some embodiments, peptide chain IV-A comprises an amino acid sequence as shown in SEQ ID NO: 37, and / or peptide chain IV-B comprises an amino acid sequence as shown in SEQ ID NO: 93.
[0360] In some embodiments, the bispecific antibody comprises two identical or different peptide chains IV-A and two identical or different peptide chains IV-B.
[0361] In some embodiments, the bispecific antibody comprises two identical peptide chains IV-A and two identical peptide chains IV-B.
[0362] 1.3.2 Fab-scFv-Configuration II
[0363] In some embodiments, the bispecific antibody comprises peptide chain IV-A and peptide chain IV-B; wherein, peptide chain IV-A comprises: a first VH, a heavy chain CH1 region, a hinge region, an Fc domain monomer, a second VH, and a second VL; and peptide chain IV-B comprises: the first VL and a light chain constant region.
[0364] In some embodiments, peptide chain IV-A comprises, from N-terminus to C-terminus, the following in sequence: (i) the first VH, the heavy chain CH1 region, the hinge region, the Fc domain monomer, the second VH, and the second VL; or (ii) the first VH, the heavy chain CH1 region, the hinge region, the Fc domain monomer, the second VL, and the second VH; peptide chain IV-B comprises, from N-terminus to C-terminus, the first VL and the light chain constant region.
[0365] In some embodiments, adjacent domains of peptide chain IV-A are optionally connected by or without a linker, and / or adjacent domains of peptide chain IV-B are optionally connected by or without a linker.
[0366] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0367] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0368] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0369] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0370] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0371] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0372] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0373] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0374] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0375] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0376] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0377] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0378] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0379] (1) The light chain constant region is selected from the λ or κ light chain constant region of human immunoglobulin;
[0380] (2) The light chain constant region contains an amino acid sequence as shown in any one of SEQ ID NO: 138-141 or 162;
[0381] (3) The heavy chain CH1 region is selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0382] (4) The heavy chain CH1 region contains an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0383] (5) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0384] (6) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0385] In some embodiments, peptide chain IV-A comprises an amino acid sequence as shown in SEQ ID NO: 62 or 64, and / or peptide chain IV-B comprises an amino acid sequence as shown in SEQ ID NO: 63.
[0386] In some embodiments, the bispecific antibody comprises two identical or different peptide chains IV-A and two identical or different peptide chains IV-B.
[0387] In some embodiments, the bispecific antibody comprises two identical peptide chains IV-A and two identical peptide chains IV-B.
[0388] 1.3.3 Fab-scFv-Configuration III
[0389] In some embodiments, the bispecific antibody comprises peptide chain IV-A and peptide chain IV-B; wherein, peptide chain IV-A comprises: a first VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; and peptide chain IV-B comprises: a second VH, a second VL, a first VL, and a light chain constant region.
[0390] In some embodiments, peptide chain IV-A comprises, from N-terminus to C-terminus, the following: the first VH, the heavy chain CH1 region, the hinge region, and the Fc domain monomer; peptide chain IV-B comprises, from N-terminus to C-terminus, (i) the second VH, the second VL, the first VL, and the light chain constant region, or (ii) the second VL, the second VH, the first VL, and the light chain constant region.
[0391] In some embodiments, adjacent domains of peptide chain IV-A are optionally connected by or without a linker, and / or adjacent domains of peptide chain IV-B are optionally connected by or without a linker.
[0392] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0393] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0394] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0395] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0396] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0397] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0398] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0399] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0400] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0401] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0402] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0403] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0404] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0405] (1) The light chain constant region is selected from the λ or κ light chain constant region of human immunoglobulin;
[0406] (2) The light chain constant region contains an amino acid sequence as shown in any one of SEQ ID NO: 138-141 or 162;
[0407] (3) The heavy chain CH1 region is selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0408] (4) The heavy chain CH1 region contains an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0409] (5) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0410] (6) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0411] In some embodiments, peptide chain IV-A comprises an amino acid sequence as shown in SEQ ID NO: 37, and / or peptide chain IV-B comprises an amino acid sequence as shown in SEQ ID NO: 38.
[0412] In some embodiments, the bispecific antibody comprises two identical or different peptide chains IV-A and two identical or different peptide chains IV-B.
[0413] In some embodiments, the bispecific antibody comprises two identical peptide chains IV-A and two identical peptide chains IV-B.
[0414] 1.4 scFv-Fab
[0415] In some implementations, the first antigen-binding domain is scFv and the second antigen-binding domain is Fab.
[0416] In some implementations, an intrachain disulfide bond can be formed between the first VH and the first VL.
[0417] In some embodiments, the first VH and the first VL are connected by a peptide linker comprising the sequence shown in SEQ ID NO: 151.
[0418] 1.4.1 scFv-Fab-Configuration I
[0419] In some embodiments, the bispecific antibody comprises peptide chain IV-A and peptide chain IV-B; wherein, peptide chain IV-A comprises: a second VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; and peptide chain IV-B comprises: a second VL, a light chain constant region, the first VH, and the first VL.
[0420] In some embodiments, peptide chain IV-A comprises, from N-terminus to C-terminus, the following: the second VH, heavy chain CH1 region, hinge region, and Fc domain monomer; peptide chain IV-B comprises, from N-terminus to C-terminus, (i) the second VL, light chain constant region, first VH, and first VL, or (ii) the second VL, light chain constant region, first VL, and first VH.
[0421] In some embodiments, adjacent domains of peptide chain IV-A are optionally connected by or without a linker, and / or adjacent domains of peptide chain IV-B are optionally connected by or without a linker.
[0422] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0423] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0424] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0425] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0426] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0427] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0428] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0429] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0430] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0431] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0432] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0433] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0434] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0435] (1) The light chain constant region is selected from the λ or κ light chain constant region of human immunoglobulin;
[0436] (2) The light chain constant region contains an amino acid sequence as shown in any one of SEQ ID NO: 138-141 or 162;
[0437] (3) The heavy chain CH1 region is selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0438] (4) The heavy chain CH1 region contains an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0439] (5) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0440] (6) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0441] In some embodiments, the bispecific antibody comprises two identical or different peptide chains IV-A and two identical or different peptide chains IV-B.
[0442] In some embodiments, the bispecific antibody comprises two identical peptide chains IV-A and two identical peptide chains IV-B.
[0443] 1.4.2 scFv-Fab-Configuration II
[0444] In some embodiments, the bispecific antibody comprises peptide chain IV-A and peptide chain IV-B; wherein, peptide chain IV-A comprises: the second VH, a heavy chain CH1 region, a hinge region, an Fc domain monomer, the first VH, and the first VL; and peptide chain IV-B comprises: the second VL and a light chain constant region.
[0445] In some embodiments, peptide chain IV-A comprises, from N-terminus to C-terminus, (i) the second VH, heavy chain CH1 region, hinge region, Fc domain monomer, first VH, and first VL, or (ii) the second VH, heavy chain CH1 region, hinge region, Fc domain monomer, first VL, and first VH; peptide chain IV-B comprises, from N-terminus to C-terminus, the second VL and light chain constant region.
[0446] In some embodiments, adjacent domains of peptide chain IV-A are optionally connected by or without a linker, and / or adjacent domains of peptide chain IV-B are optionally connected by or without a linker.
[0447] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0448] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0449] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0450] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0451] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0452] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0453] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0454] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0455] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0456] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0457] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0458] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0459] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0460] (1) The light chain constant region is selected from the λ or κ light chain constant region of human immunoglobulin;
[0461] (2) The light chain constant region contains an amino acid sequence as shown in any one of SEQ ID NO: 138-141 or 162;
[0462] (3) The heavy chain CH1 region is selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0463] (4) The heavy chain CH1 region contains an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0464] (5) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0465] (6) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0466] In some embodiments, the bispecific antibody comprises two identical or different peptide chains IV-A and two identical or different peptide chains IV-B.
[0467] In some embodiments, the bispecific antibody comprises two identical peptide chains IV-A and two identical peptide chains IV-B.
[0468] 1.4.3 scFv-Fab-Configuration III
[0469] In some embodiments, the bispecific antibody comprises peptide chain IV-A and peptide chain IV-B; wherein, peptide chain IV-A comprises: a second VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; and peptide chain IV-B comprises: the first VH, the first VL, the second VL, and a light chain constant region.
[0470] In some embodiments, peptide chain IV-A comprises, from N-terminus to C-terminus, the second VH, heavy chain CH1 region, hinge region, and Fc domain monomer; peptide chain IV-B comprises, from N-terminus to C-terminus, (i) the first VH, the first VL, the second VL, and light chain constant region, or (ii) the first VL, the first VH, the second VL, and light chain constant region.
[0471] In some embodiments, adjacent domains of peptide chain IV-A are optionally connected by or without a linker, and / or adjacent domains of peptide chain IV-B are optionally connected by or without a linker.
[0472] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0473] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0474] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0475] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0476] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0477] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0478] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0479] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0480] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0481] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0482] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0483] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0484] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0485] (1) The light chain constant region is selected from the λ or κ light chain constant region of human immunoglobulin;
[0486] (2) The light chain constant region contains an amino acid sequence as shown in any one of SEQ ID NO: 138-141 or 162;
[0487] (3) The heavy chain CH1 region is selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0488] (4) The heavy chain CH1 region contains an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0489] (5) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0490] (6) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0491] In some embodiments, the bispecific antibody comprises two identical or different peptide chains IV-A and two identical or different peptide chains IV-B.
[0492] In some embodiments, the bispecific antibody comprises two identical peptide chains IV-A and two identical peptide chains IV-B.
[0493] 1.5 DVD-Ig
[0494] In some embodiments, the bispecific antibody is in the form of DVD-Ig (Dual Variable Domain-Ig).
[0495] As used herein, the “DVD-Ig” (or “Dual Variable Domain-Ig”) structure of bispecific antibodies has the meaning commonly understood by those skilled in the art. Generally speaking, bispecific antibodies employing the “DVD-Ig” structure typically include the following core features: by tandemly expressing variable regions derived from different antigen-binding domains, a bispecific antibody molecule capable of simultaneously binding two different antigens (or epitopes) is formed (see Tarcsa, E. et al. In: Bispecific Antibodies. Kontermann RE(ed.), Springer Heidelberg Dordrecht London New York, pp. 171-185 (2011), the full text of which is incorporated herein by reference). As a non-limiting example, the light chain of a bispecific antibody in the form of "DVD-Ig" may include a tandem link of a light chain variable region of a first antigen-binding domain and a light chain variable region of a second antigen-binding domain, and its heavy chain may include a tandem link of a heavy chain variable region of a first antigen-binding domain and a heavy chain variable region of a second antigen-binding domain, thereby enabling the bispecific antibody to possess antigen-binding activity of both the first antigen-binding domain and the second antigen-binding domain.
[0496] 1.5.1 DVD-Ig-Configuration I
[0497] In some embodiments, the bispecific antibody comprises peptide chain VA and peptide chain VB; wherein, peptide chain VA comprises: a second VH, a first VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; and peptide chain VB comprises: a second VL, a first VL, and a light chain constant region.
[0498] In some embodiments, the peptide chain VA comprises, from the N-terminus to the C-terminus, the second VH, the first VH, the heavy chain CH1 region, the hinge region, and the Fc domain monomer; the peptide chain VB comprises, from the N-terminus to the C-terminus, the second VL, the first VL, and the light chain constant region.
[0499] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0500] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) nThe peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0501] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0502] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0503] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0504] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0505] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0506] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0507] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0508] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0509] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0510] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) T250Q, M428L and N434A, (v) M252Y, M428L and N434S, (vi) combinations of (i) and (iv) or (v), (vii) combinations of (ii) and (iv) or (v), (viii) combinations of (iii) and (iv) or (v).
[0511] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0512] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0513] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 101, 103, 105-106.
[0514] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0515] (1) The light chain constant region is selected from the λ or κ light chain constant region of human immunoglobulin;
[0516] (2) The light chain constant region contains an amino acid sequence as shown in any one of SEQ ID NO: 138-141 or 162;
[0517] (3) The heavy chain CH1 region is selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0518] (4) The heavy chain CH1 region contains an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0519] (5) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0520] (6) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0521] In some embodiments, the peptide chain VA comprises an amino acid sequence as shown in SEQ ID NO: 44, and / or the peptide chain VB comprises an amino acid sequence as shown in SEQ ID NO: 45.
[0522] In some embodiments, the peptide chain VA comprises an amino acid sequence as shown in SEQ ID NO: 46, and / or the peptide chain VB comprises an amino acid sequence as shown in SEQ ID NO: 47.
[0523] In some embodiments, the peptide chain VA comprises an amino acid sequence as shown in SEQ ID NO: 48, and / or the peptide chain VB comprises an amino acid sequence as shown in SEQ ID NO: 47.
[0524] In some embodiments, the peptide chain VA comprises an amino acid sequence as shown in SEQ ID NO: 49, and / or the peptide chain VB comprises an amino acid sequence as shown in SEQ ID NO: 47.
[0525] In some embodiments, the peptide chain VA comprises an amino acid sequence as shown in SEQ ID NO: 50, and / or the peptide chain VB comprises an amino acid sequence as shown in SEQ ID NO: 47.
[0526] In some embodiments, the peptide chain VA comprises an amino acid sequence as shown in SEQ ID NO: 51, and / or the peptide chain VB comprises an amino acid sequence as shown in SEQ ID NO: 52.
[0527] In some embodiments, the peptide chain VA comprises an amino acid sequence as shown in SEQ ID NO: 53, and / or the peptide chain VB comprises an amino acid sequence as shown in SEQ ID NO: 47.
[0528] In some embodiments, the peptide chain VA comprises an amino acid sequence as shown in SEQ ID NO: 54, and / or the peptide chain VB comprises an amino acid sequence as shown in SEQ ID NO: 47.
[0529] In some embodiments, the peptide chain VA comprises an amino acid sequence as shown in SEQ ID NO: 55, and / or the peptide chain VB comprises an amino acid sequence as shown in SEQ ID NO: 52.
[0530] In some embodiments, the peptide chain VA comprises an amino acid sequence as shown in SEQ ID NO: 56, and / or the peptide chain VB comprises an amino acid sequence as shown in SEQ ID NO: 47.
[0531] In some embodiments, the peptide chain VA comprises an amino acid sequence as shown in SEQ ID NO: 57, and / or the peptide chain VB comprises an amino acid sequence as shown in SEQ ID NO: 47.
[0532] In some embodiments, the peptide chain VA comprises an amino acid sequence as shown in SEQ ID NO: 163, and / or the peptide chain VB comprises an amino acid sequence as shown in SEQ ID NO: 157.
[0533] In some embodiments, the peptide chain VA comprises an amino acid sequence as shown in SEQ ID NO: 44, and / or the peptide chain VB comprises an amino acid sequence as shown in SEQ ID NO: 164.
[0534] In some embodiments, the bispecific antibody comprises two identical or different peptide chains VA and two identical or different peptide chains VB.
[0535] In some embodiments, the bispecific antibody comprises two identical peptide chains VA and two identical peptide chains VB.
[0536] 1.5.2 DVD-Ig-Configuration II
[0537] In some embodiments, the bispecific antibody comprises peptide chain VA and peptide chain VB; wherein, peptide chain VA comprises: a first VH, a second VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; and peptide chain VB comprises: a first VL, a second VL, and a light chain constant region.
[0538] In some embodiments, the peptide chain VA comprises, from the N-terminus to the C-terminus, the first VH, the second VH, the heavy chain CH1 region, the hinge region, and the Fc domain monomer; the peptide chain VB comprises, from the N-terminus to the C-terminus, the first VL, the second VL, and the light chain constant region.
[0539] In some embodiments, adjacent domains of the peptide chain VA are optionally connected by or without a linker, and / or adjacent domains of the peptide chain VB are optionally connected by or without a linker.
[0540] In some embodiments, the connectors are each independently the same or different peptide connectors (e.g., rigid peptide connectors or flexible peptide connectors).
[0541] In some embodiments, the peptide linkers are each independently selected from peptide linkers containing one or more glycine (G) and / or serine (S), for example, peptide linkers having (G) m S) n The peptide linker shown has a structure in which m and n are each independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0542] In some embodiments, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
[0543] In some embodiments, the Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4).
[0544] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4) and its variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity).
[0545] In some embodiments, the Fc domain monomer is derived from human immunoglobulin IgG1.
[0546] In some embodiments, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from:
[0547] (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii).
[0548] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0549] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of any one of (i) and (iv) to (xii), (xiv) combinations of any one of (ii) and (iv) to (xii), (xv) combinations of any one of (iii) and (iv) to (xii).
[0550] In some embodiments, compared to the Fc domain monomer of wild-type human IgG1, the variant contains an amino acid mutation selected from:
[0551] (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) T250Q, M428L and N434A, (v) M252Y, M428L and N434S, (vi) combinations of (i) and (iv) or (v), (vii) combinations of (ii) and (iv) or (v), (viii) combinations of (iii) and (iv) or (v).
[0552] In some implementations, the location of the mutation is defined by the Eu numbering system.
[0553] In some embodiments, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
[0554] In some embodiments, the bispecific antibody has one or more features selected from the following:
[0555] (1) The light chain constant region is selected from the λ or κ light chain constant region of human immunoglobulin;
[0556] (2) The light chain constant region contains an amino acid sequence as shown in any one of SEQ ID NO: 138-141 or 162;
[0557] (3) The heavy chain CH1 region is selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0558] (4) The heavy chain CH1 region contains an amino acid sequence as shown in SEQ ID NO: 136 or 137;
[0559] (5) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4);
[0560] (6) The hinge region contains an amino acid sequence as shown in SEQ ID NO: 142.
[0561] In some embodiments, the bispecific antibody comprises two identical or different peptide chains VA and two identical or different peptide chains VB.
[0562] In some embodiments, the bispecific antibody comprises two identical peptide chains VA and two identical peptide chains VB.
[0563] 2. Monoclonal antibodies
[0564] On the other hand, this application provides an antibody or antigen-binding fragment thereof that specifically binds to IL-1β, comprising:
[0565] LCDR1, LCDR2, and LCDR3 contained in VL as shown in any one of SEQ ID NO: 3-6, 10; and / or HCDR1, HCDR2, and HCDR3 contained in VH as shown in SEQ ID NO: 1 or 9. In some embodiments, the CDRs are defined according to the IMGT, Kabat, AbM, or Chothia numbering system.
[0566] In some embodiments, the antibody or its antigen-binding fragment comprises:
[0567] (a) LCDR1 containing the sequence shown in SEQ ID NO: 17, LCDR2 containing the sequence shown in SEQ ID NO: 18, and LCDR3 containing the sequence shown in SEQ ID NO: 19;
[0568] And / or,
[0569] (b) HCDR1 containing the sequence shown in SEQ ID NO: 13, HCDR2 containing the sequence shown in SEQ ID NO: 14, and HCDR3 containing the sequence shown in SEQ ID NO: 15.
[0570] In some implementations, the CDR is defined according to the Kabat numbering system.
[0571] In some embodiments, the antibody or its antigen-binding fragment comprises:
[0572] VL comprising an amino acid sequence as shown in any one of SEQ ID NO: 3-6, 10, and / or VH comprising an amino acid sequence as shown in SEQ ID NO: 1 or 9.
[0573] In some embodiments, the VL comprises an amino acid sequence as shown in any one of SEQ ID NO: 3-6, and / or the VH comprises an amino acid sequence as shown in SEQ ID NO: 1; or, the VL comprises an amino acid sequence as shown in SEQ ID NO: 10, and / or the VH comprises an amino acid sequence as shown in SEQ ID NO: 9.
[0574] On the other hand, this application also provides an antibody that specifically binds to IL-1β or an antigen-binding fragment thereof, which comprises VL and VH, wherein: the N-terminal amino acids 1-3 of the VL have at least one amino acid mutation (e.g., 1, 2, or 3) relative to the amino acid fragment of SYE.
[0575] In some embodiments, the N-terminal amino acid residue fragment of the VL is EIV, QSV, or SSE.
[0576] In some embodiments, the VL comprises LCDR1 with the sequence shown in SEQ ID NO: 16 or 17, LCDR2 with the sequence shown in SEQ ID NO: 18, and LCDR3 with the sequence shown in SEQ ID NO: 19; the VH comprises HCDR1 with the sequence shown in SEQ ID NO: 13, HCDR2 with the sequence shown in SEQ ID NO: 14, and HCDR3 with the sequence shown in SEQ ID NO: 15.
[0577] In some embodiments, the antibody or its antigen-binding fragment comprises: a VL comprising an amino acid sequence as shown in any one of SEQ ID NO: 4-6, and / or a VH comprising an amino acid sequence as shown in SEQ ID NO: 1 or 9.
[0578] In some embodiments, the antibody or its antigen-binding fragment comprises: a VL containing an amino acid sequence as shown in any one of SEQ ID NO: 154-156, and / or a VH containing an amino acid sequence as shown in SEQ ID NO: 1 or 9. In some embodiments, the antigen-binding fragment is selected from Fab, Fab', F(ab')2, Fd, Fv, disulfide-linked Fv, scFv, di-scFv, (scFv)2, diabody, and sdAb.
[0579] This application also provides multispecific molecules (such as bispecific, trispecific, tetraspecific, pentaspecific, or more specific antibodies) containing antibodies that specifically bind to IL-1β or their antigen-binding fragments, and uses of the antibodies that specifically bind to IL-1β or their antigen-binding fragments to prepare multispecific molecules (such as bispecific, trispecific, tetraspecific, pentaspecific, or more specific antibodies).
[0580] This application also provides multispecific molecules (such as bispecific, trispecific, tetraspecific, pentaspecific, or more specific antibodies) containing antibodies that specifically bind to IL-1β or their antigen-binding fragments, and uses for preparing multispecific molecules (such as bispecific, trispecific, tetraspecific, pentaspecific, or more specific antibodies) using antibodies that specifically bind to IL-1β or their antigen-binding fragments, wherein:
[0581] (1) The antibody that specifically binds to IL-1β or its antigen-binding fragment comprises LCDR1, LCDR2, and LCDR3 with sequences shown in SEQ ID NO: 16, 18, and 19, respectively, and HCDR1, HCDR2, and HCDR3 with sequences shown in SEQ ID NO: 13, 14, and 15, respectively; or
[0582] (2) The antibody that specifically binds to IL-1β or its antigen-binding fragment contains a heavy chain variable region (VH) as shown in SEQ ID NO:1 and a light chain variable region (VL) as shown in SEQ ID NO:2.
[0583] In some embodiments, the multispecific molecule specifically binds to IL-1β and additionally specifically binds to one or more other targets;
[0584] In some embodiments, the multispecific molecules specifically bind to IL-1α and IL-1β, and optionally, additionally specifically bind to one or more other targets.
[0585] 3. Derivative products
[0586] On the other hand, this application provides a multispecific molecule comprising the bispecific antibody as described above and an additional antigen-binding domain.
[0587] In some embodiments, the multispecific molecule specifically binds to IL-1α and IL-1β, and additionally specifically binds to one or more other targets.
[0588] On the other hand, this application provides the use of bispecific antibodies as described above to prepare multispecific molecules (such as trispecific, tetraspecific, pentaspecific or more specific antibodies).
[0589] In some embodiments, the multispecific molecule is a trispecific antibody, or a specific antibody with four, five, or more specificities.
[0590] On the other hand, this application provides isolated nucleic acid molecules comprising nucleotide sequences encoding bispecific antibodies, antibody-antigen-binding fragments thereof, or multispecific molecules as described above. Based on codon degeneracy in the art, in some embodiments, the nucleotide sequence can be substituted according to codon degeneracy. In some embodiments, the nucleotide sequence is codon-optimized.
[0591] It is readily understood that the bispecific antibody, antibody or its antigen-binding fragment or multispecific molecule of the present invention may be composed of one or more polypeptide chains, and there is no limitation on the number of nucleic acid molecular chains of the isolated nucleic acid molecule.
[0592] In some embodiments, the isolated nucleic acid molecule comprises a nucleotide sequence encoding the bispecific antibody of the present invention. In some embodiments, the bispecific antibody of the present invention comprises peptide chains IA, IB, IC, and ID as described above, and the isolated nucleic acid molecule comprises a first nucleotide sequence encoding peptide chain IA of the bispecific antibody of the present invention, a second nucleotide sequence encoding peptide chain IB, a third nucleotide sequence encoding peptide chain IC, and a fourth nucleotide sequence encoding peptide chain ID, wherein the first nucleotide sequence, the second nucleotide sequence, the third nucleotide sequence, and the fourth nucleotide sequence are present on the same or different nucleic acid molecules. In some embodiments, the bispecific antibody of the present invention comprises peptide chains II-A, II-B, II-C, and II-D as described above, and the isolated nucleic acid molecule comprises a first nucleotide sequence encoding peptide chain II-A of the bispecific antibody of the present invention, a second nucleotide sequence encoding peptide chain II-B, a third nucleotide sequence encoding peptide chain II-C, and a fourth nucleotide sequence encoding peptide chain II-D, wherein the first nucleotide sequence, the second nucleotide sequence, the third nucleotide sequence, and the fourth nucleotide sequence are present on the same or different nucleic acid molecules. In some embodiments, the bispecific antibody of the present invention comprises peptide chain III-A, peptide chain III-B, and peptide chain III-C as described above, wherein the isolated nucleic acid molecule comprises a first nucleotide sequence encoding peptide chain III-A of the bispecific antibody of the present invention, a second nucleotide sequence encoding peptide chain III-B thereof, and a third nucleotide sequence encoding peptide chain III-C thereof, wherein the first nucleotide sequence, the second nucleotide sequence, and the third nucleotide sequence are present on the same or different nucleic acid molecules. In some embodiments, the bispecific antibody of the present invention comprises peptide chain IV-A, peptide chain IV-B, and peptide chain IV-C as described above, wherein the isolated nucleic acid molecule comprises a first nucleotide sequence encoding peptide chain IV-A of the bispecific antibody of the present invention, a second nucleotide sequence encoding peptide chain IV-B thereof, and a third nucleotide sequence encoding peptide chain IV-C thereof, wherein the first nucleotide sequence, the second nucleotide sequence, and the third nucleotide sequence are present on the same or different nucleic acid molecules. In some embodiments, the bispecific antibody of the present invention comprises peptide chain VA, peptide chain VB, and peptide chain VC as described above, wherein the isolated nucleic acid molecule comprises a first nucleotide sequence encoding peptide chain VA of the bispecific antibody of the present invention, a second nucleotide sequence encoding peptide chain VB thereon, and a third nucleotide sequence encoding peptide chain VC thereon, wherein the first nucleotide sequence, the second nucleotide sequence, and the third nucleotide sequence are present on the same or different nucleic acid molecules.
[0593] On the other hand, this application provides a vector containing the isolated nucleic acid molecules as described above.
[0594] In some implementations, the vector is a cloning vector or an expression vector.
[0595] It is readily understood that the isolated nucleic acid molecules described above can exist in the vector in any form. For example, when the isolated nucleic acid molecule contains multiple nucleotide sequences encoding different peptide chains, these multiple nucleotide sequences can be located in the same vector or in different vectors. There are no restrictions on the orientation, relative position, or connection method of the multiple nucleotide coding sequences on the vector.
[0596] On the other hand, this application provides a host cell containing isolated nucleic acid molecules or vectors as described above.
[0597] On the other hand, this application provides a method for preparing the bispecific antibody, antibody or antigen-binding fragment or multispecific molecule as described above, comprising culturing host cells as described above under conditions that allow expression of the bispecific antibody, antibody or antigen-binding fragment or multispecific molecule, and recovering the bispecific antibody, antibody or antigen-binding fragment or multispecific molecule from the cultured host cell culture.
[0598] On the other hand, this application provides conjugates comprising, as described above, bispecific antibodies, antibodies or their antigen-binding fragments or multispecific molecules, and a conjugate portion thereto.
[0599] In some embodiments, the coupling portion is selected from therapeutic agents.
[0600] On the other hand, this application provides a pharmaceutical composition comprising the bispecific antibody as described above, or the antibody or its antigen-binding fragment as described above, or the multispecific molecule as described above, or the nucleic acid molecule isolated as described above, or the carrier as described above, or the host cell as described above, or the conjugate as described above, and a pharmaceutically acceptable carrier and / or excipient.
[0601] In some embodiments, the pharmaceutical composition further comprises additional pharmaceutically active agents, such as anti-inflammatory drugs or immunosuppressants. In some embodiments, the bispecific antibody, antibody or its antigen-binding fragment, or multispecific molecule is provided with the additional pharmaceutically active agent as a separate component or as a mixture thereof.
[0602] 4. Therapeutic applications
[0603] On the other hand, this application provides the use of the bispecific antibody as described above, or the antibody or its antigen-binding fragment as described above, or the multispecific molecule as described above, or the isolated nucleic acid molecule as described above, or the carrier as described above, or the host cell as described above, or the conjugate as described above, or the pharmaceutical composition as described above in the preparation of a medicament for use in the prevention and / or treatment of diseases associated with IL-1α and / or IL-1β in a subject.
[0604] In some embodiments, the disease is characterized by elevated IL-1α and / or IL-1β expression and / or excessive IL-1α and / or IL-1β activity.
[0605] In some implementations, the disease is an inflammatory disease or an autoimmune disease.
[0606] In some embodiments, the disease is selected from: juvenile idiopathic arthritis (JIA), systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease (AOSD), cold pyrrolizine-associated periodic syndrome (CAPS), rheumatoid arthritis (RA), osteoarthritis, gout, gouty arthritis (e.g., acute gouty arthritis), atopic dermatitis, interstitial lung disease (ILD) (e.g., connective tissue disease-associated interstitial lung disease (CTD-ILD), such as rheumatoid arthritis-associated interstitial lung disease (RA-ILD), systemic sclerosis-associated interstitial lung disease (SSc-ILD), etc.), acne, familial Mediterranean fever (FMF), periodic seizures. Fever syndrome, neonatal multisystem inflammatory diseases, tumor necrosis factor receptor 1-associated periodic fever syndrome (TRAPS), inflammatory bowel disease, recurrent pericarditis, IL-1 receptor antagonist deficiency, Mueller-Weir syndrome, urticaria, Crohn's disease, ulcerative colitis, multiple sclerosis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis, graft-versus-host disease, hidradenitis suppurativa (HS, such as moderate to severe hidradenitis suppurativa), endometriosis (EM), adenomyosis, endometriosis with adenomyosis, polyarticular juvenile idiopathic arthritis, chronic aseptic osteomyelitis, systemic sclerosis (also known as scleroderma), Behçet's syndrome, uveitis (such as non-infectious uveitis (NIU), infectious uveitis), psoriasis, neurodegenerative diseases, atherosclerosis, metabolic diseases, aging, tumors, and thyroid diseases.
[0607] In some embodiments, the disease is selected from: endometriosis, adenomyosis, and endometriosis with adenomyosis; the treatment includes non-sequential use of the drug of the present invention (e.g., for adolescents or patients with early-stage endometriosis), or sequential use of the drug of the present invention after hormone therapy (HT) (especially for patients with late-stage endometriosis).
[0608] In some implementations, the disease is selected from: hidradenitis suppurativa (HS, such as moderate to severe hidradenitis suppurativa) and endometriosis.
[0609] In some implementations, the subject is a mammal, such as a human.
[0610] In some embodiments, the bispecific antibody, antibody or its antigen-binding fragment, multispecific molecule, isolated nucleic acid molecule, vector, host cell, conjugate, or pharmaceutical composition is administered in combination with another pharmaceutically active agent, for example, simultaneously, separately, or sequentially.
[0611] In some embodiments, the additional pharmaceutically active agent is an anti-inflammatory drug or an immunosuppressant.
[0612] On the other hand, this application provides a method for preventing and / or treating diseases associated with IL-1α and / or IL-1β in a subject, the method comprising administering to a subject in need an effective amount of the bispecific antibody as described above, or the antibody as described above or its antigen-binding fragment, or the multispecific molecule as described above, or the isolated nucleic acid molecule as described above, or the vector as described above, or the host cell as described above, or the conjugate as described above, or the pharmaceutical composition as described above.
[0613] In some embodiments, the disease is characterized by elevated IL-1α and / or IL-1β expression and / or excessive IL-1α and / or IL-1β activity.
[0614] In some implementations, the disease is an inflammatory disease or an autoimmune disease.
[0615] In some embodiments, the disease is selected from: juvenile idiopathic arthritis (JIA), systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease (AOSD), cold pyrrolizine-associated cycle syndrome (CAPS), rheumatoid arthritis (RA), osteoarthritis, gout, gouty arthritis (e.g., acute gouty arthritis), atopic dermatitis, interstitial lung disease (ILD) (e.g., connective tissue disease-associated interstitial lung disease (CTD-ILD), such as rheumatoid arthritis-associated interstitial lung disease (RA-ILD), systemic sclerosis-associated interstitial lung disease (SSc-ILD), etc.), acne, familial Mediterranean fever (FMF), and cycle syndrome. Febrile syndrome, neonatal multisystem inflammatory diseases, tumor necrosis factor receptor 1-associated periodic fever syndrome (TRAPS), inflammatory bowel disease, recurrent pericarditis, IL-1 receptor antagonist deficiency, Mueller-Weir syndrome, urticaria, Crohn's disease, ulcerative colitis, multiple sclerosis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis, graft-versus-host disease, hidradenitis suppurativa (HS, such as moderate to severe hidradenitis suppurativa), endometriosis, adenomyosis, endometriosis with adenomyosis, polyarticular juvenile idiopathic arthritis, chronic aseptic osteomyelitis, systemic sclerosis (also known as scleroderma), Behçet's syndrome, uveitis (such as non-infectious uveitis (NIU), infectious uveitis), psoriasis, neurodegenerative diseases, atherosclerosis, metabolic diseases, aging, tumors, and thyroid diseases.
[0616] In some embodiments, the disease is selected from: endometriosis, adenomyosis, and endometriosis with adenomyosis; the treatment includes non-sequential use of the drug of the present invention (e.g., for adolescents or patients with early-stage endometriosis), or sequential use of the drug of the present invention after hormone therapy (HT) (especially for patients with late-stage endometriosis).
[0617] In some implementations, the disease is selected from: hidradenitis suppurativa (HS, such as moderate to severe hidradenitis suppurativa) and endometriosis.
[0618] In some implementations, the subject is a mammal, such as a human.
[0619] In some embodiments, the bispecific antibody, antibody or its antigen-binding fragment, multispecific molecule, isolated nucleic acid molecule, vector, host cell, conjugate, or pharmaceutical composition is administered in combination with another pharmaceutically active agent, for example, simultaneously, separately, or sequentially.
[0620] In some embodiments, the additional pharmaceutically active agent is an anti-inflammatory drug or an immunosuppressant.
[0621] The bispecific antibodies, antibody or antigen-binding fragments, multispecific molecules, isolated nucleic acid molecules, carriers, host cells, conjugates, or pharmaceutical compositions of the present invention can be formulated into any dosage form known in the medical field, such as tablets, pills, suspensions, emulsions, solutions, gels, capsules, powders, granules, elixirs, lozenges, suppositories, injections (including injection solutions, sterile powders for injection, and concentrated solutions for injection), inhalers, sprays, etc. Preferred dosage forms depend on the intended route of administration and therapeutic use. The antibodies or antigen-binding fragments, multispecific molecules, bispecific antibodies, isolated nucleic acid molecules, carriers, host cells, conjugates, or pharmaceutical compositions of the present invention should be sterile and stable under the conditions of manufacture and storage. A preferred dosage form is an injection. Such injections may be sterile injectable solutions. For example, a sterile injectable solution can be prepared by incorporating the required dose of the antibody of the present invention into a suitable solvent, and optionally, simultaneously incorporating other desired components (including, but not limited to, pH adjusters, surfactants, adjuvants, ionic strength enhancers, isotonic agents, preservatives, diluents, or any combination thereof), followed by sterile filtration. Alternatively, the sterile injectable solution can be prepared as a sterile lyophilized powder (e.g., by vacuum drying or freeze-drying) for easy storage and use. Such sterile lyophilized powders can be dispersed in a suitable carrier, such as sterile pyrogen-free water, before use.
[0622] Furthermore, the bispecific antibodies, antibody or antigen-binding fragments, multispecific molecules, isolated nucleic acid molecules, vectors, host cells or conjugates of the present invention can be present in the pharmaceutical composition in unit dose form for ease of administration.
[0623] The bispecific antibodies, antibody or antigen-binding fragments, multispecific molecules, isolated nucleic acid molecules, vectors, host cells, conjugates, or pharmaceutical compositions of the present invention can be administered by any suitable method known in the art, including but not limited to oral, oral, sublingual, ocular, topical, parenteral, rectal, intrathecal, intracytoplasmic reticulum groove, groin, intrabladder, topical (e.g., powder, ointment, or drops), or nasal routes. However, for many therapeutic uses, the preferred route / method of administration is parenteral administration (e.g., intravenous, subcutaneous, intraperitoneal, intramuscular). Those skilled in the art will understand that the route and / or method of administration will vary depending on the intended purpose. In a preferred embodiment, the bispecific antibodies, antibody or antigen-binding fragments, multispecific molecules, isolated nucleic acid molecules, vectors, host cells, conjugates, or pharmaceutical compositions of the present invention are administered by intravenous infusion or injection.
[0624] The pharmaceutical compositions of the present invention may include a "therapeuticly effective amount" of the bispecific antibody, antibody or antigen-binding fragment, multispecific molecule, isolated nucleic acid molecule, vector, host cell, or conjugate of the present invention. A "therapeuticly effective amount" refers to an amount sufficient to cure or at least partially prevent the disease and its complications in a patient already suffering from the disease. The therapeutically effective amount of the bispecific antibody, antibody or antigen-binding fragment, multispecific molecule, isolated nucleic acid molecule, vector, host cell, or conjugate of the present invention may vary depending on factors such as the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general characteristics such as age, weight, and sex, the method of drug administration, and other concurrent treatments, etc.
[0625] In this invention, the dosing regimen can be adjusted to obtain the optimal target response (e.g., therapeutic response). For example, it can be administered as a single dose, multiple times over a period of time, or the dose can be reduced or increased proportionally according to the urgency of the treatment situation.
[0626] 5. Detection Applications
[0627] The bispecific antibody of the present invention can specifically bind to IL-1α and IL-1β, thereby being used to detect the presence or level of IL-1α and / or IL-1β in a sample.
[0628] The antibody or its antigen-binding fragment of the present invention can specifically bind to IL-1β, thereby enabling it to be used to detect the presence or level of IL-1β in a sample.
[0629] Therefore, in another aspect, the present invention provides a kit comprising the bispecific antibody of the present invention, or the antibody or its antigen-binding fragment thereof. In some embodiments, the bispecific antigen, or antibody, or its antigen-binding fragment thereof of the present invention is labeled with a detectable marker. In a preferred embodiment, the kit further comprises a second antibody that specifically recognizes the bispecific antibody, or antibody, or its antigen-binding fragment thereof of the present invention. Preferably, the second antibody further comprises a detectable marker.
[0630] In another aspect, the present invention provides a method for detecting the presence or level of IL-1α and / or IL-1β in a sample, comprising the step of using the bispecific antibody of the present invention. In a preferred embodiment, the bispecific antibody of the present invention is further labeled with a detectable marker. In another preferred embodiment, the method further comprises detecting the bispecific antibody of the present invention using a reagent labeled with a detectable marker. The method may be used for diagnostic purposes or non-diagnostic purposes (e.g., the sample is a cell sample, not a sample from a patient). In some embodiments, the method comprises contacting the sample with the bispecific antibody of the present invention under conditions that allow the formation of a complex between the bispecific antibody of the present invention and IL-1α and / or IL-1β, and detecting the formation of the complex.
[0631] In another aspect, the present invention provides a method for detecting the presence or level of IL-1β in a sample, comprising the step of using an antibody or antigen-binding fragment of the present invention. In a preferred embodiment, the antibody or antigen-binding fragment of the present invention is further labeled with a detectable marker. In another preferred embodiment, the method further comprises detecting the antibody or antigen-binding fragment of the present invention using a reagent labeled with a detectable marker. The method can be used for diagnostic purposes or non-diagnostic purposes (e.g., the sample is a cell sample, not a sample from a patient). In some embodiments, the method comprises contacting the sample with the bispecific antibody of the present invention under conditions that allow the formation of a complex between the antibody or antigen-binding fragment of the present invention and IL-1β, and detecting the formation of the complex.
[0632] In another aspect, the use of the bispecific antibody of the present invention in the preparation of a kit for detecting the presence or level of IL-1α and / or IL-1β in a sample is provided.
[0633] In another aspect, the use of the antibody or antigen-binding fragment thereof of the present invention in the preparation of a kit for detecting the presence or level of IL-1β in a sample is provided.
[0634] 6. Polypeptides
[0635] On the other hand, this application provides a polypeptide comprising an Fc domain variant, wherein the Fc domain variant contains an amino acid mutation selected from the group consisting of the Fc domain of wild-type human IgG1:
[0636] (i) T250Q / M428L / N434A,
[0637] (ii) V308P / M428L / N434S,
[0638] (iii) T307A / M428L / N434S,
[0639] (iv) M252Y / M428L / N434S,
[0640] (v) M252Y / V308P / N434S
[0641] (vi) T307A / V308P / M428L / N434S,
[0642] (vii)T250Q / V308P / N434S,
[0643] The numbering follows the Eu numbering scheme.
[0644] In some embodiments, the Fc domain of the wild-type human IgG1 contains an amino acid sequence as shown in SEQ ID NO: 97.
[0645] In some embodiments, the Fc domain variant further comprises an amino acid mutation selected from any one or a combination of the following:
[0646] (i) L234R and / or G236R,
[0647] (ii) D356E and / or L358M
[0648] (iii) D356E, L358M, L234R and / or G236R.
[0649] In some embodiments, the Fc domain variant comprises an amino acid sequence as shown in any one of SEQ ID NO: 98, 101-106, 109, 112, 113, 118-129, 131, 135.
[0650] In some embodiments, the Fc domain variant is in monomeric or dimeric form (including homodimers or heterodimers).
[0651] In some embodiments, the Fc domain variant comprises a first monomer and a second monomer, the first monomer and the second monomer comprising an amino acid sequence selected from the group consisting of:
[0652] (i) SEQ ID NO: 135 and SEQ ID NO: 118,
[0653] (ii) SEQ ID NO: 119 and SEQ ID NO: 120,
[0654] (iii) SEQ ID NO: 121 and SEQ ID NO: 122,
[0655] (iv) SEQ ID NO: 101 and SEQ ID NO: 101,
[0656] (v) SEQ ID NO: 103 and SEQ ID NO: 103,
[0657] (vi) SEQ ID NO: 105 and SEQ ID NO: 105,
[0658] (vii) SEQ ID NO: 106 and SEQ ID NO: 106.
[0659] In some embodiments, the peptide has a prolonged half-life, improved PK, and / or altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activity) compared to peptides containing the Fc domain of wild-type human IgG1.
[0660] On the other hand, this application provides an antibody or antibody fragment comprising the aforementioned polypeptide.
[0661] In some embodiments, the antibody is a monoclonal antibody or a multispecific antibody (e.g., a bispecific antibody).
[0662] In some embodiments, the bispecific antibody specifically binds to IL-1α and IL-1β.
[0663] In some embodiments, the bispecific antibody configuration is either DVD-Ig (Dual Variable Domain-Ig) or KIH (Knob-into-Hole).
[0664] In some embodiments, the antibody or antibody fragment is selected from the above-described bispecific antibodies, antibodies or their antigen-binding fragments, or multispecific molecules.
[0665] In some embodiments, the antibody or antibody fragment is selected from the bispecific antibodies described in the “1.1 Knob-into-Hole (KIH) Structure” section above.
[0666] In some embodiments, the antibody or antibody fragment is selected from the bispecific antibodies described in the “1.5 DVD-Ig” section above.
[0667] In some embodiments, the antibody or antibody fragment has a prolonged half-life, improved PK, and / or altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activity) compared to antibodies or antibody fragments containing the Fc domain of wild-type human IgG1.
[0668] The inventors of this application unexpectedly discovered that the Fc domain variant, when combined with various antibody configurations, can significantly improve the stability of the antibody, exhibiting a general stability enhancement effect. Furthermore, a significant stability enhancement effect was found when combined with specific antibody configurations (e.g., DVD-Ig or KIH bispecific antibodies), which is speculated to be due to a potential synergistic effect between the Fc domain variant and the specific antibody configuration.
[0669] Specifically, in a mouse blood assay system, when the Fc domain variant is combined with a DVD-Ig (Dual Variable Domain-Ig) bispecific antibody, the antibody half-life (T1 / 2) is extended by at least 3 times and the AUC(0-t) is increased by at least 2 times compared to the wild-type isoform antibody. When the Fc domain variant is combined with a KIH (Knob-into-Hole) bispecific antibody, the antibody half-life (T1 / 2) is extended by at least 50% and the AUC(0-t) is increased by at least 40%.
[0670] In another aspect, this application provides a pharmaceutical composition comprising the aforementioned polypeptide, antibody or antibody fragment, and a pharmaceutically acceptable carrier and / or excipient.
[0671] In another aspect, this application provides the use of the above-described peptides, antibodies, or antibody fragments, or pharmaceutical compositions in the preparation of a medicament for the prevention and / or treatment in a subject of diseases associated with IL-1α and / or IL-1β. In yet another aspect, this application also provides a method for the prevention and / or treatment in a subject of diseases associated with IL-1α and / or IL-1β, the method comprising administering an effective amount of the above-described peptides, antibodies, or antibody fragments, or pharmaceutical compositions to a subject in need of such treatment.
[0672] In some embodiments, the disease is characterized by elevated IL-1α and / or IL-1β expression and / or excessive IL-1α and / or IL-1β activity.
[0673] In some implementations, the disease is an inflammatory disease or an autoimmune disease.
[0674] In some embodiments, the disease is selected from: juvenile idiopathic arthritis (JIA), systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease (AOSD), cold pyrrolizine-associated cycle syndrome (CAPS), rheumatoid arthritis (RA), osteoarthritis, gout, gouty arthritis (e.g., acute gouty arthritis), atopic dermatitis, interstitial lung disease (ILD) (e.g., connective tissue disease-associated interstitial lung disease (CTD-ILD), such as rheumatoid arthritis-associated interstitial lung disease (RA-ILD), systemic sclerosis-associated interstitial lung disease (SSc-ILD), etc.), acne, familial Mediterranean fever (FMF), and cycle syndrome. Febrile syndrome, neonatal multisystem inflammatory diseases, tumor necrosis factor receptor 1-associated periodic fever syndrome (TRAPS), inflammatory bowel disease, recurrent pericarditis, IL-1 receptor antagonist deficiency, Mueller-Weir syndrome, urticaria, Crohn's disease, ulcerative colitis, multiple sclerosis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis, graft-versus-host disease, hidradenitis suppurativa (HS, such as moderate to severe hidradenitis suppurativa), endometriosis, adenomyosis, endometriosis with adenomyosis, polyarticular juvenile idiopathic arthritis, chronic aseptic osteomyelitis, systemic sclerosis (also known as scleroderma), Behçet's syndrome, uveitis (such as non-infectious uveitis (NIU), infectious uveitis), psoriasis, neurodegenerative diseases, atherosclerosis, metabolic diseases, aging, tumors, and thyroid diseases.
[0675] In some embodiments, the disease is selected from: endometriosis, adenomyosis, and endometriosis with adenomyosis; the treatment includes non-sequential use of the drug of the present invention (e.g., for adolescents or patients with early-stage endometriosis), or sequential use of the drug of the present invention after hormone therapy (HT) (especially for patients with late-stage endometriosis).
[0676] In some embodiments, the disease is selected from: hidradenitis suppurativa (HS, such as moderate to severe hidradenitis suppurativa) and endometriosis. In some embodiments, the subject is a mammal, such as a human.
[0677] 7. Mutation Applications
[0678] On the other hand, this application provides the application of amino acid mutations selected from the following group in prolonging the half-life / improving PK or effector function in antibodies, antibody fragments, or fusion proteins:
[0679] (i) T250Q / M428L / N434A,
[0680] (ii) V308P / M428L / N434S,
[0681] (iii) T307A / M428L / N434S,
[0682] (iv) M252Y / M428L / N434S,
[0683] (v) M252Y / V308P / N434S
[0684] (vi) T307A / V308P / M428L / N434S,
[0685] (vii)T250Q / V308P / N434S,
[0686] The numbering follows the Eu numbering scheme, and the amino acid mutation is compared to the Fc domain of wild-type human IgG1.
[0687] In some embodiments, the Fc domain of the wild-type human IgG1 comprises an amino acid sequence as shown in SEQ ID NO: 97. In some embodiments, the improved effector function is selected from enhanced, reduced, or eliminated ADCC activity, CDC activity, and / or ADCP activity.
[0688] In some embodiments, the amino acid mutation further comprises an amino acid mutation selected from any one or a combination of the following:
[0689] (i) L234R and / or G236R,
[0690] (ii) D356E and / or L358M
[0691] (iii) D356E, L358M, L234R and / or G236R.
[0692] Terminology Definition
[0693] In this invention, unless otherwise stated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the virological, biochemical, and immunological laboratory procedures used herein are all standard procedures widely used in their respective fields. To better understand this invention, definitions and explanations of relevant terms are provided below.
[0694] When the terms “for example,” “such as,” “like,” “including,” “contains,” or variations thereof are used herein, these terms will not be considered restrictive terms but will be interpreted as meaning “but not limited to” or “not limited to.”
[0695] Unless otherwise specified herein or clearly contradicted by the context, the terms “an” and “a kind” as well as “the” and similar designations shall be interpreted to cover both the singular and the plural in the context of describing the invention (especially in the context of the following claims).
[0696] As used herein, the term "antibody" is used in the broadest sense to encompass a wide variety of antibody structures, including but not limited to monoclonal antibodies (MAbs), polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, provided they exhibit the desired antigen-binding activity. For example, an immunoglobulin molecule can consist of two pairs of polypeptide chains, each pair having one light chain (LC) and one heavy chain (HC). Antibody light chains can be classified as κ (kappa) and λ (lambda) light chains. Heavy chains can be classified as μ, δ, γ, α, or ε, and antibody isotypes are defined as IgM, IgD, IgG, IgA, and IgE, respectively. Within both the light and heavy chains, variable and constant regions are linked by a "J" region of approximately 12 or more amino acids, and the heavy chain also contains a "D" region of approximately 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (VH) and a heavy chain constant region (CH). The heavy chain constant region consists of three domains (CH1, CH2, and CH3). Each light chain consists of a variable region (VL) and a constant region (CL). The constant region consists of a single CL domain. While not directly involved in antibody-antigen binding, the constant domain exhibits various effector functions, such as mediating the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The VH and VL regions can be further subdivided into highly degenerated regions (called complementarity-determining regions (CDRs)) interspersed with more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4, from the amino terminus to the carboxyl terminus. The variable regions (VH and VL) of each heavy / light chain pair form the antigen-binding sites. The distribution of amino acids in different regions or domains can follow the definitions in Kabat, Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987 and 1991)), or Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al. (1989) Nature 342:878-883.
[0697] In this article, unless the context clearly indicates otherwise, when referring to the term "antibody," it includes not only the complete antibody but also the antigen-binding fragment of the antibody.
[0698] As used in this article, the term "complementarity-determining region" or "CDR" refers to the amino acid residues in the antibody variable region responsible for antigen binding. The precise boundaries of these amino acid residues can be defined according to various numbering systems known in the art, such as the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), the AbM numbering system (Martin ACR, Cheetham JC, Rees AR (1989) Modeling antibody hypervariable loops: A combined algorithm. Proc Natl AcadSci USA 86:9268-9272), the Chothia numbering system (Chothia & Lesk (1987) J. Mol. Biol.196:901-917; Chothia et al. (1989) Nature 342:878-883), or the IMGT numbering system (Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003). For a given antibody, those skilled in the art will readily identify the CDR as defined by each numbering system. Furthermore, the correspondence between different numbering systems is well known to those skilled in the art (see, for example, Lefranc et al., Dev. Comparat. Immunol. 27:55-77, 2003).
[0699] In this invention, the CDR contained in the antibody or antigen-binding fragment thereof can be determined according to various numbering systems known in the art. In some embodiments, the CDR contained in the antibody or antigen-binding fragment thereof is preferably determined by the IMGT, Kabat, AbM, or Chothia numbering system.
[0700] As used herein, the term “framework region” or “FR” residues refer to those amino acid residues in the antibody variable region other than the CDR residues as defined above.
[0701] The term "antibody" is not limited to any particular method of producing antibodies. For example, it includes recombinant antibodies, monoclonal antibodies, and polyclonal antibodies. Antibodies can be different isotypes of antibodies, such as IgG (e.g., IgG1, IgG2, IgG3, or IgG4 subtypes), IgA1, IgA2, IgD, IgE, or IgM antibodies.
[0702] As used herein, the term “antigen-binding fragment” of an antibody refers to a molecule other than the full-length antibody, which includes a portion of the full-length antibody that binds to the antigen bound to the full-length antibody. For example, an antigen-binding fragment may be a polypeptide fragment of a full-length antibody that retains the ability to specifically bind to the same antigen bound to the full-length antibody, and / or competes with the full-length antibody for specific binding to the antigen; this is also referred to as an “antigen-binding moiety.” See also Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed., Raven Press, NY (1989), which is incorporated herein by reference in its entirety for all purposes. Antigen-binding fragments of antibodies can be generated by recombinant DNA technology or by enzymatic or chemical cleavage of intact antibodies. Non-limiting examples of antigen-binding fragments include Fab, Fab', Fab'-SH, F(ab')2, Fd, Fv, dAb and complementarity-determining region (CDR) fragments, single-chain antibodies (e.g., scFv), chimeric antibodies, diabody, linear antibody, nanobody (technology from Domantis), domain antibody (technology from Ablynx), and peptides containing at least a portion of an antibody sufficient to confer specific antigen-binding ability to the peptide. Engineered antibody variants are reviewed in Holliger et al., 2005; Nat Biotechnol, 23: 1126-1136.
[0703] As used herein, the term "Fab fragment" refers to an antibody fragment consisting of VL, VH, CL, and CH1 domains.
[0704] As used herein, the term "Fc region" refers to the antibody fragment formed by the second and third constant regions of the first heavy chain of the antibody. The Fc fragment of an antibody has a variety of different functions but does not participate in antigen binding.
[0705] As used herein, the term “scFv” refers to a single polypeptide chain containing VL and VH domains linked by a linker (see, for example, Bird et al., Science 242:423-426 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Pluckthun, The Pharmacology of Monoclonal Antibodies, Vol. 113, eds. Roseburg and Moore, Springer-Verlag, New York, pp. 269-315 (1994)). Such scFv molecules may have a general structure: NH2-VL-linker-VH-COOH or NH2-VH-linker-VL-COOH.
[0706] Each of the aforementioned antibody fragments retains the ability to specifically bind to the same antigen bound by the full-length antibody, and / or competes with the full-length antibody for specific binding to the antigen. In this document, those skilled in the art can use known conventional techniques to obtain antigen-binding fragments (e.g., the antibody fragments described above) from a given antibody (e.g., the antibody fragments provided in this invention), and specifically screen for antigen-binding fragments in the same manner as for whole antibodies.
[0707] As used herein, the term "multispecific molecule" refers to a molecule (e.g., an antibody) that has binding specificity to multiple different antigens (or epitopes). As used herein, the term "bispecific antibody" refers to an antibody that has binding specificity to two different antigens (or epitopes), which is a conjugate formed by a first antibody (or a fragment thereof) and a second antibody (or a fragment thereof) or an antibody analogue through a conjugation arm, the conjugation being, but not limited to, chemical reactions, gene fusion, and enzymatic reactions.
[0708] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and its target antigen. The strength or affinity of a specific binding interaction can be measured by the equilibrium dissociation constant (KD) or half-maximal effective concentration (EC50) of the interaction. 50 )express.
[0709] The specific binding properties between two molecules can be determined using methods known in the art. One method involves measuring the rate of formation and dissociation of the antigen binding site / antigen complex. Both the “binding rate constant” (ka or kon) and the “dissociation rate constant” (kdis or koff) can be calculated from the concentration and the actual rates of association and dissociation (see Malmqvist M, Nature, 1993, 361:186-187). The ratio of kdis / kon is equal to the dissociation constant KD (see Davies et al., Annual Rev Biochem, 1990; 59:439-473). The values of KD, kon, and kdis can be measured using any effective method. In some embodiments, the dissociation constant can be measured using bioluminescent interferometry (e.g., the ForteBio Octet method). Alternatively, surface plasmon resonance techniques (e.g., Biacore) or Kinexa can be used to measure the dissociation constant.
[0710] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which polynucleotides can be inserted. When a vector enables the expression of a protein encoded by the inserted polynucleotide, it is called an expression vector. Vectors can be introduced into host cells through transformation, transduction, or transfection, allowing the genetic material elements they carry to be expressed in the host cells. Vectors are well-known to those skilled in the art and include, but are not limited to: plasmids; phage particles; Cos plasmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC), or P1-derived artificial chromosomes (PAC); bacteriophages such as λ phage or M13 phage; and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retrotranscriptoviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomaviruses (such as SV40). A vector may contain multiple elements controlling expression, including but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. Additionally, a vector may contain a replication initiation site.
[0711] Expression and cloning vectors contain nucleic acid sequences that enable the vector to replicate in one or more selected host cells. Typically, in cloning vectors, this sequence is the one that enables the vector to replicate independently of the host chromosomal DNA, and it includes an origin of replication or an autonomous replication sequence. As used herein, the term "expression vector" refers to a vector containing recombinant polynucleotides that include expression regulatory sequences effectively linked to the nucleotide sequence to be expressed. Expression vectors contain sufficient cis-acting elements for expression; other elements for expression may be provided by the host cell or an in vitro expression system. Expression vectors include all those known in the art, such as entrapments, plasmids (e.g., naked or contained in liposomes), and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses).
[0712] As used herein, the term "host cell" refers to cells that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, NSO cells, Vero cells, HeLa cells, COS cells, CHO cells (e.g., CHO-K1, CHO-S, CHO DXB11, ExpiCHO, CHO DG44 or CHO-EBNA cells), ExpiCHO cells, HEK293 cells, Expi293 cells, BHK cells, and MDCKII cells.
[0713] The twenty common amino acids referred to herein are written in accordance with conventional usage. See, for example, Immunology-ASynthesis (2nd Edition, ES Golub and DR Gren, Eds., Sinauer Associates, Sunderland, Mass. (1991)), which is incorporated herein by reference. In this invention, the terms “polypeptide” and “protein” have the same meaning and are used interchangeably. Furthermore, in this invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.
[0714] As used herein, the term "pharmaceutically acceptable carrier and / or excipient" means a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, which is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to: pH adjusters, surfactants, adjuvants, ionic strength enhancers, diluents, osmotic pressure maintaining agents, absorption delaying agents, and preservatives. For example, pH adjusters include, but are not limited to, phosphate buffers. Surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween-80. Ionic strength enhancers include, but are not limited to, sodium chloride. Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, etc. Osmotic pressure maintaining agents include, but are not limited to, sugars, NaCl, and their analogues. Absorption delaying agents include, but are not limited to, monostearates and gelatin. Diluents include, but are not limited to, water, aqueous buffers (such as buffered saline), alcohols, and polyols (such as glycerol). Stabilizers have the meaning commonly understood by those skilled in the art for stabilizing the desired activity of the active ingredient in a pharmaceutical product, including but not limited to monosodium glutamate, gelatin, SPGA, sugars (such as sorbitol, mannitol, starch, sucrose, lactose, dextran, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dried whey, albumin, or casein) or their degradation products (such as lactalbumin hydrolysate).
[0715] As used herein, the term "prevention" refers to a method implemented to prevent or delay the occurrence of a disease, condition, or symptom (e.g., an inflammatory disease) in a subject. As used herein, the term "treatment" refers to a method implemented to obtain a beneficial or desired clinical outcome. For the purposes of this invention, beneficial or desired clinical outcomes include, but are not limited to, alleviating symptoms, reducing the extent of disease, stabilizing (i.e., no longer worsening) the state of disease, delaying or slowing the progression of disease, improving or alleviating the state of disease, and relieving symptoms (whether partial or complete), whether detectable or undetectable. Furthermore, "treatment" can also refer to prolonged survival compared to the expected survival (if no treatment was received).
[0716] As used herein, the term "subject" refers to a mammal, such as a primate mammal, like a human. In some embodiments, the subject (e.g., a human) suffers from an inflammatory disease, or is at risk of suffering from such a disease.
[0717] As used herein, the term "effective amount" means an amount sufficient to achieve, or at least partially achieve, the desired effect. For example, an effective amount for preventing disease (e.g., an inflammatory disease) means an amount sufficient to prevent, stop, or delay the onset of a disease (e.g., an inflammatory disease); an effective amount for treating disease means an amount sufficient to cure or at least partially stop the disease and its complications in a patient already suffering from the disease. Determining such an effective amount is entirely within the capabilities of those skilled in the art. For example, an effective amount for therapeutic purposes will depend on the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general characteristics such as age, weight, and sex, the manner of administration of the drug, and other concurrent treatments, etc.
[0718] As used herein, the term "effector function" refers to the biological activity attributable to the antibody's Fc region (either the native Fc region or the Fc region of an amino acid sequence variant), which varies across antibody isotypes. Examples of antibody effector functions include, but are not limited to: Fc receptor binding affinity, antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent phagocytosis (ADCP), downregulation of cell surface receptors (e.g., B cell receptors), B cell activation, cytokine secretion, and the half-life / clearance of antibodies and antigen-antibody complexes. Methods for altering antibody effector functions are known in the art, such as by introducing mutations into the Fc region.
[0719] As used herein, the term “antibody-dependent cell-mediated cytotoxicity (ADCC)” refers to a form of cytotoxicity in which Ig binds specifically to the antigen-attached target cells by binding to Fc receptors (FcRs) present on cytotoxic cells (such as NK cells, neutrophils, or macrophages), and then kills the target cells by secreting cytotoxins.
[0720] As used in this article, the term “complement-dependent cytotoxicity (CDC)” refers to complement-mediated cytotoxicity, which involves the activation of the classical complement pathway by the binding of specific antibodies to corresponding antigens on the cell membrane surface to form a complex. The resulting membrane attack complex exerts a lytic effect on the target cell.
[0721] As used herein, the term "antibody-dependent phagocytosis (ADCP)" refers to an antibody-mediated immune effector mechanism characterized by: a specific antibody recognizing and binding to an antigenic epitope on the surface of a target cell via its antigen-binding domain; subsequently, effector cells specifically interact with the antibody's Fc region via their surface-expressed Fcγ receptors (FcγRs), thereby initiating endocytosis and resulting in the phagocytosis and clearance of the target cell. The effector cells include, but are not limited to, populations of immune cells with phagocytic function such as macrophages and neutrophils.
[0722] In this document, "combination" includes therapies that can be administered separately, such as those formulated separately for individual drug administration (e.g., those provided in kits), and therapies that can be administered together as a single formulation (i.e., "co-formulation"). The antibodies or antigen-binding fragments or multispecific molecules or bispecific antibodies or conjugates of the present invention can be used in combination with at least one other (active) agent in any manner. In such combination therapies, the various active agents often have different complementary mechanisms of action, and the combination therapy may result in a synergistic effect.
[0723] Unless otherwise specified herein or clearly contradicted by the context, “A, B and / or C” or similar expressions should be understood as “A, B, C or any combination thereof”, for example, it can be understood as any one of A, B, C, A and B, A and C, B and C, A and B and C.
[0724] Beneficial effects of the invention
[0725] The bispecific antibody provided by this invention can specifically bind to IL-1α and IL-1β with high affinity and can effectively downregulate or block the activity of IL-1α and IL-1β (e.g., can inhibit or block the activation of downstream signaling pathways induced by IL-1α and / or IL-1β, and inhibit or block the secretion of cytokines induced by IL-1α and / or IL-1β).
[0726] In some embodiments, the bispecific antibody of the present invention also has better drugability (e.g., better purity), easier purification, better physicochemical properties (e.g., better stability) and / or extended half-life, thereby enabling its effective application in commercial production and clinical treatment.
[0727] The embodiments of the present invention will now be described in detail with reference to the accompanying drawings and examples. However, those skilled in the art will understand that the following drawings and examples are for illustrative purposes only and are not intended to limit the scope of the invention. Various objects and advantages of the present invention will become apparent to those skilled in the art from the following detailed description of the drawings and preferred embodiments. Attached Figure Description
[0728] Figure 1a Antibody inhibits LPS-stimulated PBMCs from secreting the cytokine IL-6.
[0729] Figure 1b Antibody inhibits LPS-stimulated PBMCs from secreting the cytokine IL-8.
[0730] Figure 1c Antibody inhibits LPS-stimulated PBMCs from secreting the cytokine TNF-α.
[0731] Figure 1d Antibody inhibits LPS-stimulated PBMCs from secreting the cytokine IFN-γ.
[0732] Figure 2 : Antibody blocking activity in mice. Detailed Implementation
[0733] The invention will now be described with reference to the following embodiments, which are intended to illustrate the invention (and not limit it).
[0734] Unless otherwise specified, the molecular biology experimental methods and immunoassays used in this invention are substantially in accordance with the methods described in J. Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and F.M. Ausubel et al., A Concise Guide to Molecular Biology, 3rd Edition, John Wiley & Sons, Inc., 1995. Those skilled in the art will appreciate that the examples are described by way of illustration and are not intended to limit the scope of the invention.
[0735] Example 1: Mutation and Identification of Anti-IL-1β Monoclonal Antibody
[0736] 1.1 Anti-IL-1β monoclonal antibody mutation
[0737] Using the sequence of anti-IL-1β monoclonal antibody mAb001 (from patent application CN106928354A, the heavy chain variable region and light chain variable region sequences are shown in SEQ ID NO: 1 and 2, respectively) as a template, analysis revealed that the cysteine (C) at position 34 of its light chain variable region was an unpaired amino acid. This cysteine was mutated into the structurally similar amino acid serine (S). The constant region was obtained using human IgG4 CH (SEQ ID NO: 153) and λ chain CL (SEQ ID NO: 138). The protein was expressed and purified by Baiying Biotechnology to obtain a new anti-IL-1β monoclonal antibody mAb002 (the light chain variable region sequence is shown in SEQ ID NO: 3). Furthermore, the inventors of this application discovered that mAb001 expression exhibits a deletion of three amino acids (SYE) at the N-terminus of the light chain when expressed in certain signal peptides (e.g., MHSSALLCCLVLLTGVRA, SEQ ID NO: 152). Through sequence design, these three amino acids at the N-terminus of the light chain were mutated, such as mutating SYE to EIV (mAb003, light chain variable region sequence as shown in SEQ ID NO: 4), mutating to QSV (mAb004, light chain variable region sequence as shown in SEQ ID NO: 5), or mutating to SSE (mAb005, light chain variable region sequence as shown in SEQ ID NO: 6). In addition, monoclonal antibodies mAb007, mAb008, and mAb009 were designed, which contain only the above three light chain N-terminal mutations (replacing the light chain N-terminal SYE with EIV, QSV, and SSE). The constant regions were human IgG4 CH (SEQ ID NO: 153) and λCL (SEQ ID NO: 138). The protein expression and purification were entrusted to Baiying Biotechnology. The molecular weight of the light chain was determined by mass spectrometry as follows: 50 µg of the sample was diluted with 20 mM ammonium bicarbonate to a protein concentration of approximately 1 mg / mL. 1 μl of glycosidase was added, and the mixture was incubated at 37 °C for 4 h. After separation by UPLC, the sample was detected by a Triple TOF 6600 mass spectrometer (AB Sciex) using an electrospray ionization (ESI) source. The positive ion mode was used, with a collision voltage of 20 V, a declustering voltage of 150 V, a spray voltage of 5500 V, a curtain gas pressure of 35 psi, and an ionization temperature of 550 °C. The scanning mode was TOF MS, and the mass scan range was 350–4000 (m / z).
[0738] The results are shown in Table 1. Under the same signal peptide expression conditions, the three amino acids at the N-terminus of the light chain of the anti-IL-1β monoclonal antibody were not deleted after mutation.
[0739] Table 1. Mass spectrometry detection results
[0740] 1.2 ELISA detection
[0741] This experiment verified the binding activity of anti-IL-1β monoclonal antibody to human IL-1β using ELISA. The specific method is as follows: The antibody was coated with 1 µg / ml human IL-1β (KACTUS, IL1-HE40B) overnight at 4℃, blocked with 1% BSA at 37℃ for 2 h, and the antibody to be tested was diluted 5-fold starting from 100 nM, with 8 concentration spots as primary antibodies. 100 μl of primary antibody was added to each well, and the mixture was incubated at 37℃ for 1 h. 100 μl of Goat Anti-Human IgG (H+L) secondary antibody (Jackson, 109-035-088) (1:5000 dilution) was added to each well, and the mixture was incubated at 37℃ for 1 h. The sample was then detected at 450 nm.
[0742] The results are shown in Table 2. The binding activity of the anti-IL-1β monoclonal antibody to human IL-1β before and after the mutation was basically the same, indicating that the above mutation did not have an adverse effect on the binding activity of the anti-IL-1β monoclonal antibody to human IL-1β.
[0743] Table 2. ELISA binding activity of anti-IL-1β monoclonal antibodies against human IL-1β
[0744] 1.3 Detection of antibody activity in inhibiting cytokine secretion by MRC-5 cells
[0745] This experiment investigated the effect of mutation on the stability of anti-IL-1β monoclonal antibody. The specific method is as follows: Anti-IL-1β monoclonal antibodies before and after mutation were subjected to accelerated treatment at 55℃ and 60℃ for 24 hours, respectively. The inhibitory effect of anti-IL-1β monoclonal antibody on IL-6 secretion by MRC-5 cells was detected using the following method: MRC-5 cells (purchased from ATCC) were adjusted to a density of 40,000 cells / mL using EMEM (ATCC, 302003) experimental medium containing 10% FBS (Gibco, A5669701), and 50 μL / well was seeded in 96-well flat-bottom cell culture plates (CORNING, 3599), i.e., 2000 cells / well. The test antibody was diluted with experimental medium (EMEM + 10% FBS), and 50 μL / well was added to the 96-well cell culture plates, starting at a final concentration of 20 nM, with 8-fold dilutions and 8 gradients. Human IL-1β (R&D Systems, 201-LB) was diluted in the experimental medium, with 50 μL added to each well to achieve a final stimulation concentration of 25.5 pg / mL. The total experimental volume was 150 μL per well. The cells were incubated at 37°C with 5% CO2 for 20-24 hours. The next day, the cell supernatant was collected by centrifugation, and IL-6 levels were detected by ELISA (ELISA kit purchased from Dayou, catalog number: 1110603). The antibody's ability to inhibit IL-6 secretion was calculated using the formula: Inhibition rate (%) = 100% × [(stimulation - sample) / (stimulation - blank)]. The stimulation group (no antibody, only human IL-1β) was used as the highest stimulation value; the blank group (no IL-1β or antibody) served as the background level.
[0746] The results are shown in Table 3. The anti-IL-1β monoclonal antibody showed better tolerance to accelerated treatment after mutation, indicating that the stability of the anti-IL-1β monoclonal antibody was significantly improved after mutation.
[0747] Table 3. Cell viability after accelerated treatment with anti-IL-1β monoclonal antibody
[0748] Example 2: Construction of bispecific antibodies based on different structures of anti-IL-1β monoclonal antibodies and anti-IL-1α monoclonal antibodies
[0749] 2.1 Construction of dual-resistance systems with different structures
[0750] Based on anti-IL-1β monoclonal antibodies mAb001, mAb002, mAb003 and anti-IL-1α monoclonal antibody X3 (from patent application EP0659766A1, with heavy chain variable region and light chain variable region as shown in SEQ ID NO: 11 and 12, respectively), various forms of bispecific antibodies were constructed, such as knob-into-hole (KIH) bispecific antibodies, DVD-Ig bispecific antibodies, Ig-scFv bispecific antibodies, Crossmab bispecific antibodies, FIT-Ig bispecific antibodies, and other forms of bispecific antibodies. The control antibody cAb005 (i.e., Lutikizumab, which is a bispecific antibody specifically binding to IL-1α and IL-1β) was purchased from MCE, catalog number: HY-P99721. The heavy chain variable region (SEQ ID NO: 7) and light chain variable region (SEQ ID NO: 8) of cAb005, which bind IL-1β, were linked to the constant regions of human IgG1 CH (SEQ ID NO: 97) and κCL (SEQ ID NO: 140), respectively, to construct the anti-IL-1β monoclonal antibody mAb006. The CDR and variable region sequences of each anti-IL-1β monoclonal antibody and anti-IL-1α monoclonal antibody, which serve as the basis for the bispecific antibody, are shown in Table 4, and the molecular structure / sequence information of each bispecific antibody is shown in Table 5. Furthermore, based on the constructed bispecific antibody bAb006, its IL-1β binding domain was replaced with the IL-1β binding domain of mAb001 to obtain the bispecific antibody bAb012. The heavy and light chain amino acid sequences of bAb012 are shown in SEQ ID NO: 44 and SEQ ID NO: 164, respectively.
[0751] Table 4. CDRs (according to the Kabat numbering system) and variable region sequences of various anti-IL-1β and anti-IL-1α monoclonal antibodies
[0752] Table 5. Bispecific antibody structure / sequence information
[0753]
[0754]
[0755]
[0756]
[0757]
[0758]
[0759]
[0760]
[0761]
[0762]
[0763]
[0764]
[0765]
[0766] Note:
[0767] 1. The IL-1α binding domain of all bispecific antibodies shown in the table is based on anti-IL-1α monoclonal antibody X3;
[0768] 2. Each domain of the heavy chain (e.g., HC1, HC2) and light chain (e.g., LC1, LC2) of the bispecific antibodies shown in the table may optionally include a linker sequence. The linker sequence between adjacent domains of the antibody light and heavy chains can be derived from the full-length sequences of the antibody light and heavy chains. An exemplary linker sequence may be selected from any of the amino acid sequences shown in SEQ ID NO: 143-151, wherein the amino acid sequence of SEQ ID NO: 148 is “SS”.
[0769] 3. “VH1” and “VL1” represent VH and VL that specifically bind to IL-1α, and “VH2” and “VL2” represent VH and VL that specifically bind to IL-1β.
[0770] 2.2 Purity Detection of Bispecific Antibiotics
[0771] The purity of the bispecific antibody was determined using SEC-HPLC and SDS-PAGE, as follows.
[0772] SDS-PAGE electrophoresis procedure: The protein sample is pre-treated to be non-reduced and diluted according to the given protein concentration. The protein is diluted to 0.4 mg / ml with ultrapure water. 30 μl of sample is taken and 10 μl of 4× non-reduced sample buffer is added, and the mixture is stirred well. The non-reduced sample is boiled in a 100℃ water bath for 1 min, cooled, and then added to the gel wells. The gel is incubated at 160V for 40 min. The gel is then removed, stained, and destained before gel imaging.
[0773] SEC-HPLC Procedure: SEC experiments were performed using an LC-20AT high-performance liquid chromatograph and a gel permeation column. The experimental conditions were as follows: flow rate 1 ml / min, injection volume 20 μl, column temperature 35℃, detection wavelengths 214 nm and 280 nm, and acquisition time 15 min. The water was replaced with the mobile phase (50 mmol / L PB-300 mmol / L NaCl, pH 7.4), and the flow rate was slowly increased to 1.000 ml / min until the baseline stabilized. 25 μl of antibody was injected into the corresponding numbered vial. The vial was placed in the appropriate position on the instrument, and the injection time was 15 min. The data were analyzed, processed, and saved. The mobile phase was then replaced with deionized water, and the sample was rinsed for 1.5 h.
[0774] The results are shown in Table 6. The purity of bispecific antibodies purified in one step for asymmetric structures is often relatively low. Commonly used KIH-type bispecific antibodies have a purity of approximately 70%, such as the control bispecific antibodies cAb007 (kappa-kappa KIH) and cAb008 (kappa-lambda KIH) based on the IL-1β binding domain sequence of Lutikizumab, both with SEC purities of around 75%. However, unexpectedly, the KIH-type bispecific antibodies bAb007 and bAb008, respectively derived from the anti-IL-1β monoclonal antibody mAb001 in Example 1, achieved SEC purities exceeding 90%. Other bispecific antibodies, bAb001, bAb004, bAb006, bAb009, and bAb010, all achieved SEC purities greater than 90% after one-step purification. The results above demonstrate that the purity of bispecific antibodies using various structures of anti-IL-1β monoclonal antibody mAb001 and its derived molecular sequences is superior to that of control bispecific antibody molecules with the same structure.
[0775] Table 6. Comparison of purity of bispecific antibodies purified in one step based on different IL-1β binding domain sequences
[0776] 2.3 Detection of Bispecific Antibody Cell Activity
[0777] This experiment used MRC-5 cells for activity detection. The IL-1β monostimulation experiment was the same as in section 1.3 of Example 1; for IL-1α monostimulation, human IL-1α (nearshore protein, C070) was used at a final concentration of 25.5 pg / mL, and the final concentrations for co-stimulation of IL-1α and IL-1β were 60 pg / mL and 25.5 pg / mL, respectively. The experimental system, detection, and calculation methods were the same as in section 1.3 of Example 1.
[0778] The results are shown in Table 7. The activities of bAb001, bAb002, bAb004, bAb006, bAb007, bAb008 and bAb009 in inhibiting IL-1β stimulation and in co-stimulating MRC-5 secretion of IL-6 with IL-1α and IL-1β were significantly better than those of the control bispecific antibody molecules (cAb series) with the same structure, and were also better than the control cAb005 (Lutikizumab).
[0779] Table 7. Comparison of bispecific antibody cell activities based on different IL-1β binding domain sequences
[0780] Example 3: Screening for Fc mutations with extended half-life
[0781] To obtain a molecule with a significantly prolonged half-life, constant region Fc mutations were performed on a bispecific antibody in the form of KIH (bAb008) and DVD-Ig (bAb005). Wild-type (WT) and nine different Fc mutants were tested: M428L / N434S (LS), M252Y / S254T / T256E (YTE), T250Q / M428L / N434A (QLA), and V308. The proteins were prepared by expressing P / M428L / N434S (PLS), T307A / M428L / N434S (ALS), T307A / V308P / M428L / N434S (APLS), M252Y / M428L / N434S (YLS), M252Y / V308P / N434S (YPS), and T250Q / V308P / N434S (QPS).
[0782] 3.1 FcRn Affinity Detection
[0783] To detect the affinity of different Fc mutants for FcRn, the affinity was determined using Biacore at pH 6.0. Specific procedures included: using a CM5 chip with amino-conjugated anti-his antibody; hFcRn-his capture temperature of 25℃; sample flow rate of 30 μl / min; capture time of 60 s; and a capture volume of approximately 20-100 RU. For the antibody sample, the detection temperature was 25℃; sample flow rate was 30 μl / min; binding time was 180 s; dissociation time was 300 s; regeneration time was 90-120 s; and the regeneration buffer was Glycine 1.5.
[0784] The results are shown in Tables 8 and 9. Under pH 6.0 conditions, the affinity of each bispecific antibody molecule containing different Fc mutants for hFcRn was significantly increased compared with bispecific antibody molecules containing wild-type Fc domains.
[0785] 3.2 Cell viability detection
[0786] To investigate the effects of different Fc mutations on antibody activity, a method similar to that described in section 2.3 of Example 2 was used to evaluate the inhibitory effects of the antibody on IL-1α and IL-1β by detecting its inhibition of IL-6 secretion in MRC-5 cells. The final concentrations of the stimulants human IL-1α and human IL-1β are shown in Tables 8 and 9, respectively.
[0787] The results are shown in Tables 8 and 9. All different bispecific antibody molecules showed good cell activity, and different Fc mutations did not adversely affect the cell activity of the bispecific antibodies.
[0788] Table 8. KD values and cell viability assays of bispecific antibodies using different Fc mutant KIH forms
[0789] Table 9. KD values and cell viability assays of bispecific antibodies in DVD-Ig form using different Fc mutants.
[0790] Example 4: Pharmacokinetic Study in Mice
[0791] 4.1 Male mice were administered a single intravenous injection of 5 mg / kg of the bispecific antibody molecule. Whole blood was collected before and at different time points after administration (Pre(-24h), 4h, 24h, 48h, 72h, 96h, 168h, 336h, 504h, 672h, 840h) to prepare serum. The drug concentration in the serum was measured, and pharmacokinetic curves were plotted. PK parameters were calculated using an NCA model to study the pharmacokinetic characteristics of the bispecific antibody molecule in mice. Wild-type C57BL / 6J mice (Vitollivan, catalog number 213) were used for bAb009, while FcRn humanized mice (Biocytogen, catalog number 110001) were used for the other bispecific antibody molecules.
[0792] The results are shown in Table 10. The dual antibody molecules using different Fc mutants all exhibited superior PK properties compared to molecules using the wild-type (WT) Fc domain. In the KIH structure, the LS, ALS, and QLA mutations showed better performance; in the DVD-Ig structure, the QLA and YLS mutations were more prominent.
[0793] Table 10. Results of mouse pharmacokinetic studies
[0794] 4.2 Male C57BL / 6J mice (Vitollivar, catalog number 213) were administered a single subcutaneous injection of 10 mg / kg of the drug. Whole blood was collected at different time points before and after drug administration to prepare serum. The fusion protein Rilonacept (purchased from MCE, catalog number: HY-108822) was administered at the following times: before administration, 5 min, 2 h, 4 h, 8 h, 24 h, 48 h, 72 h, 120 h, 168 h, 240 h, and 336 h; and the bispecific antibody molecule was administered at the following times: before administration, 5 min, 2 h, 8 h, 24 h, 72 h, 120 h, 168 h, 240 h, 336 h, 504 h, and 672 h. Serum drug concentrations were measured, and pharmacokinetic curves were plotted to study the pharmacokinetic characteristics of the bispecific antibody molecule in mice.
[0795] The results are shown in Table 11. All bispecific antibodies exhibited good PK properties and were significantly superior to the fusion protein Rilonacept.
[0796] Table 11. Results of mouse pharmacokinetic studies
[0797] Example 5: In vitro activity detection of bispecific antibodies
[0798] 5.1 Antibody inhibits IL-6 secretion by MRC-5 cells
[0799] The antibody activity detection method is the same as section 2.3 of Example 2.
[0800] The results are shown in Table 12. The inhibitory activity of bAb006 and bAb008 against IL-1α stimulation was comparable to that of the control antibody cAb005 (Lutikizumab), while the inhibitory activity of bAb009 against IL-1α stimulation was superior to that of cAb005 (Lutikizumab). The inhibitory activities of bAb006, bAb008, and bAb009 against IL-1β activity, as well as against co-stimulation by IL-1α and IL-1β, were significantly superior to those of cAb005 (Lutikizumab). Furthermore, as shown in Tables 13-14, the inhibitory activities of bAb010 and bAb011 against co-stimulation by IL-1α and IL-1β were also significantly superior to those of cAb005 (Lutikizumab). Under conditions of co-stimulation by IL-1α and IL-1β, anti-IL-1α monoclonal antibodies or anti-IL-1β monoclonal antibodies can only partially inhibit the activity of IL-1α and IL-1β. The maximum inhibition rates of monoclonal antibodies mAb001 and X3 were 66.13% and 76.54%, respectively, which were lower than those of bispecific antibodies.
[0801] Table 12. Results of antibody-induced inhibition of IL-6 secretion activity in MRC-5 cells stimulated by IL-1α and IL-1β.
[0802] Table 13. Results of antibody-induced inhibition of IL-6 secretion activity in MRC-5 cells stimulated by IL-1α and IL-1β.
[0803] Table 14. Results of antibody-induced inhibition of IL-6 secretion activity in MRC-5 cells stimulated by IL-1α and IL-1β.
[0804] 5.2 Antibody inhibits IL-8 secretion by MRC-5 cells
[0805] Cell culture, plating, and antibody dilution were performed as described in section 2.3 of Example 2. The final concentrations of the stimulants human IL-1α and human IL-1β are shown in the table. The total experimental volume was 150 μL / well, incubated at 37°C in a 5% CO2 incubator for 20-24 hours. The cell supernatant was collected by centrifugation the following day, and IL-8 levels were detected by ELISA (ELISA reagent purchased from Dayou, catalog number: 1110803). The inhibition rate was calculated using the same method as in section 2.3 of Example 2. Anakinra, the control, was purchased from MCE, catalog number: HY-108841.
[0806] The results are shown in Tables 15 and 16. All the bispecific antibodies showed good effects in inhibiting the secretion of IL-8 by MRC-5 cells, and were superior to cAb005 (Lutikizumab) and Anakinra.
[0807] Table 15. Results of antibody-induced inhibition of IL-8 secretion activity in MRC-5 cells stimulated by IL-1α and IL-1β.
[0808] Table 16. Results of antibody bAb007 inhibiting the IL-8 secretion activity of MRC-5 cells stimulated by IL-1α and IL-1β.
[0809] 5.3 Antibody inhibits IL-6 secretion by IL-1 stimulated PBMCs
[0810] Frozen healthy human PBMCs (Peripheral blood mononuclear cells, purchased from Ruibai Biotechnology) were revived and their density was adjusted to 4 × 10⁶ cells / year using RPMI-1640 (Gibco, C11875500BT) complete medium containing 10% FBS. 6Cells were seeded at 50 μL / well in 96-well cell culture plates (CORNING, 3799). Antibodies were diluted with complete culture medium (RPMI-1640 + 10% FBS), and 50 μL / well was added to each well, starting at a final concentration of 20 nM, with 4-fold dilutions in 8 gradients. Human IL-1α (nearshore protein, C070) or human IL-1β (R&D Systems, 201-LB) was diluted with complete culture medium, and 50 μL / well was added to the corresponding experimental well. The final concentration for individual stimulation was 2 ng / mL, and the final concentrations for co-stimulation of IL-1α and IL-1β were 0.5 ng / mL and 2 ng / mL, respectively. The total experimental volume was 150 μL / well, and the cells were incubated at 37°C in a 5% CO2 incubator for 20–24 hours. The next day, the cell supernatant was collected by centrifugation, and IL-6 levels were detected by ELISA (ELISA kit purchased from Daiyou, catalog number: 1110603). The method for calculating the inhibition rate is the same as in section 2.3 of Example 2.
[0811] The results are shown in Table 17. The IL-1α inhibition activity of bAb006 was comparable to that of the control antibody cAb005, while its IL-1β inhibition activity and its activity against the co-stimulation of IL-1α and IL-1β were superior to those of the control antibody cAb005.
[0812] Table 17. Results of antibody-induced inhibition of IL-1-stimulated PBMC IL-6 secretion activity assay
[0813] 5.4 Antibody inhibits LPS-stimulated PBMC secretion of multiple cytokines
[0814] Resuscitated cryopreserved healthy human PBMCs (Peripheral blood mononuclear cells, purchased from Ruibai Biotechnology) were adjusted to a density of 2 × 10⁶ cells / mL using RPMI-1640 (Gibco, C11875500BT) complete medium containing 10% FBS. 6Cells / mL were seeded at 100 μL / well in 96-well cell culture plates (CORNING, 3799). The antibody to be tested was diluted with complete medium (RPMI-1640 + 10% FBS), with 50 μL / well of antibody dilution added to the corresponding well. The initial antibody concentration was 4 nM, 3-fold dilution, 7 gradients, or 1 nM, 4-fold dilution, 4 gradients. LPS (lipopolysaccharide, Sigma, L4391) was diluted with complete medium (RPMI-1640 + 10% FBS), with 50 μL / well added to the corresponding well, resulting in a final LPS concentration of 24 pg / mL. Cell culture plates were incubated at 37°C in a 5% CO2 incubator for 24 or 48 hours. The cell culture supernatant was collected by centrifugation. The 24-hour supernatant was used for ELISA detection of IL-6 (ELISA kit purchased from Dayou, catalog number: 1110603), IL-8 (ELISA kit purchased from Dayou, catalog number: 1110803), and TNF-α (ELISA kit purchased from R&D Systems, catalog number: STA00D). The 48-hour supernatant was used for ELISA detection of IFN-γ (ELISA kit purchased from R&D Systems, catalog number: SIF50C). The ability of the antibody to inhibit cytokine secretion was calculated using the formula: Inhibition rate (%) = 100% × [(stimulation - sample) / (stimulation - blank)], where the stimulation group (no antibody, only LPS) was used as the highest value of the stimulation; the blank group (cell control without LPS and antibody) was used as the background.
[0815] The results are shown in Table 18. bAb006 showed a significantly better ability than the control cAb005 (Lutikizumab) to inhibit LPS-stimulated PBMC secretion of IL-6, IL-8, TNF-α and IFN-γ.
[0816] Table 18. Results of antibody inhibition of LPS-stimulated PBMC secretion of multiple cytokines
[0817] Other examples Figure 1a As shown in Figure 1, bAb006, bAb008, and bAb009 showed superior ability to inhibit the secretion of IL-6, IL-8, TNF-α, and IFN-γ compared to cAb005 (Lutikizumab), Rilonacept, and Anakinra, with the differences in their ability to inhibit the secretion of TNF-α and IFN-γ being particularly significant.
[0818] Example 6: Blocking activity of bispecific antibodies in mice
[0819] Female C57BL / 6J mice (Vitolliwa, catalog number: 213) aged 6-8 weeks were used, with 5-6 mice per group. On day 0, the mice were intraperitoneally injected with the drug at the doses shown in Tables 17-19, while the negative control group was injected with saline. 24 hours later, all model mice were intraperitoneally injected with 100 ng / mouse each of human IL-1α (nearshore protein, C070) and human IL-1β (R&D Systems, 201-LB). The negative control group was injected with saline. Two hours after injection, mouse serum was collected, and the serum IL-6 content was detected by ELISA (R&D, M6000B-1). The ability of the antibody to inhibit IL-6 secretion in vivo was calculated using the formula: Inhibition rate (%) = 100% × [(model group - sample group) / (model group - blank group)], where the model group, which was injected with only cytokines and no antibody, was used as the maximum value of stimulation; the blank group was a negative control without injection of cytokines and antibodies, used as the background.
[0820] The results are shown in Tables 19-21. All bispecific antibodies could inhibit the release of IL-6 induced by IL-1α and IL-1β stimulation in vivo, and their inhibitory activity was superior to that of the control cAb005 (Lutikizumab).
[0821] Table 19 Inhibition rate in the mouse PD model (Pharmacodynamics Model)
[0822] Note: " / " indicates that it was not detected.
[0823] Table 20 Inhibition rate in mouse PD model
[0824] Table 21 Inhibition rate in mouse PD model
[0825] Example 7: Pharmacokinetic Study of Bisoxane in Cynomolgus Monkeys
[0826] Male Naïve cynomolgus monkeys (Medix) were administered a single subcutaneous injection of a bispecific antibody molecule at a dose of 1 mg / kg. Whole blood was collected before and at different time points after administration (pre-dose, 4h, 24h, 48h, 72h, 96h, 120h, 168h, 216h, 264h, 336h, 504h, 672h, 840h, 1008h, 1512h, and 1848h after administration) to prepare serum. The drug concentration in the serum was measured, and a pharmacokinetic curve was plotted. The pharmacokinetic parameters were calculated using an NCA model to study the pharmacokinetic characteristics of the bispecific antibody molecule in cynomolgus monkeys.
[0827] The results are shown in Table 22. All bispecific antibody molecules exhibited good PK characteristics.
[0828] Table 22 Crab-eating macaques vs. crab-eating macaques
[0829] Example 8: Stability Optimization of Ig-scFv Structure
[0830] To increase the stability of the bispecific antibody molecule bAb009, the linker of VH-VL in the Ig-scFv structure was replaced with GGGGSGGSGGCPPCGGSGG (SEQ ID NO: 151), and VH M43C and VL G100C mutations were added to obtain the modified bispecific antibody molecule bAb009-1 (the heavy chain variable region and light chain variable region of the IL-1β binding domain are shown in SEQ ID NO: 9 and 10, respectively). The protein was treated at 55℃ and 60℃ for 24 h, and the binding of the antibody to human IL-1β and IL-1α was verified by ELISA. The specific method is as follows: Coat with 1 µg / ml human IL-1β (KACTUS, IL1-HE40B) or human IL-1α (nearshore protein, GMP-C070), incubate overnight at 4℃, block with 1% BSA at 37℃ for 2 h, start with 100 nM of the antibody to be tested, dilute 5 times, and use 8 concentration spots as primary antibodies, add 100 μl of primary antibody to each well, incubate at 37℃ for 1 h, add 100 μl of Goat Anti-Human IgG (H+L) secondary antibody (Jackson, 109-035-088) (1:5000 dilution) to each well, incubate at 37℃ for 1 h, and detect at 450 nm.
[0831] The results are shown in Table 23. After treatment at 55℃, the binding activity of the modified molecule bAb009-1 was basically the same as that before treatment, indicating that its stability was significantly better than that of bAb009. The improvement was more significant on the IL-1β binding domain side.
[0832] Table 23. Structural stability optimization based on bAb009
[0833] Example 9: Study on the activity of bispecific antibodies based on mAb001 monoclonal antibody
[0834] Based on the anti-IL-1β monoclonal antibody mAb001 sequence from Example 1 and the anti-IL-1α monoclonal antibody X3 from Example 2, various forms of bispecific antibodies GSR006, GSR007, GSR008 (i.e., bAb001), and GSR010 (i.e., bAb010) were constructed. The positive control was Lutikizumab (i.e., GSR005 / cAb005). The sequence information of GSR005, GSR008, and GSR010 is shown in Table 5, and the sequence information of GSR006 and GSR007 is shown in Table 25. The bispecific antibody construction method is the same as in Example 2.
[0835]
[0836] 9.1 Antibody inhibits IL-6 secretion by MRC-5 cells
[0837] This experiment used MRC-5 cells for activity detection. The final concentrations of IL-1α and IL-1β co-stimulation were 25.5 pg / mL and 25.5 pg / mL, respectively. The experimental system, detection, and calculation methods are the same as those in section 2.3 of Example 2.
[0838] The results are shown in Table 25. GSR006, GSR007, GSR008, and GSR010 showed better inhibition of IL-6 secretion by MRC-5 and co-stimulation of IL-1α and IL-1β than the control GSR005 (Lutikizumab).
[0839] The results are shown in Table 25.
[0840] Table 25. Results of antibody-induced inhibition of IL-6 secretion activity in MRC-5 cells stimulated by IL-1α and IL-1β.
[0841] 9.2 Antibody inhibits IL-6 secretion by IL-1 stimulated PBMCs
[0842] Cell culture, plating, and antibody dilution were performed as described in section 5.3 of Example 5. The final concentrations of the stimulants human IL-1α and human IL-1β are shown in the table. The total experimental volume was 100 μL / well, and the cells were incubated at 37°C in a 5% CO2 incubator for 24 hours. The cell supernatant was collected by centrifugation the next day, and the IL-6 level was detected by ELISA (R&D, S6050). The inhibition rate was calculated as described in section 5.3 of Example 5.
[0843] The results are shown in Table 26. All the bispecific antibodies showed good effects in inhibiting IL-6 secretion from MRC-5 cells, and were superior to Lutikizumab.
[0844] Table 26. Results of antibody-induced inhibition of IL-6 secretion by PBMCs stimulated by IL-1α and IL-1β.
[0845] 9.3 Blocking activity of bispecific antibodies in mice
[0846] Female C57BL / 6J mice (Vitolliwa, catalog number: 213) aged 6-8 weeks were used, with 5 mice in each group. On day 0, mice were intraperitoneally injected with the drug at a dose of 0.3 mg / kg, while the negative control group received saline. 24 hours later, all model mice were intraperitoneally injected with 100 ng / mouse each of human IL-1α (nearshore protein, C070) and human IL-1β (R&D Systems, 201-LB). The negative control group received saline. Serum was collected 2 hours after injection, and the serum IL-6 level was detected by ELISA (R&D, M6000B-1). The ability of the antibody to inhibit IL-6 secretion in vivo was calculated using the formula: Inhibition rate (%) = 100% × [(Model group - Sample group) / (Model group - Blank group)], where the model group (no antibody injection, only cytokine injection) was used as the maximum value of stimulation; the blank group (no cytokine and antibody injection) served as the negative control and was used as the background.
[0847] The results are shown in Table 27 and Figure 2 As shown, each of the bispecific antibodies can inhibit the release of IL-6 induced by IL-1α and IL-1β stimulation in vivo, and the inhibitory activity is superior to that of the control GSR005 (Lutikizumab).
[0848] Table 27 Inhibition rate in mouse PD model
[0849] Although specific embodiments of the invention have been described in detail, those skilled in the art will understand that various modifications and variations can be made to the details based on all the published teachings, and all such changes are within the scope of protection of the invention. The entire scope of the invention is given by the appended claims and any equivalents thereof.
Claims
1. A bispecific antibody comprising a first antigen-binding domain that specifically binds to IL-1α (interleukin-1α) and a second antigen-binding domain that specifically binds to IL-1β (interleukin-1β); wherein The first antigen-binding domain includes a first light chain variable region (VL) and a first heavy chain variable region (VH), wherein the first VL and the first VH together form a domain capable of specifically binding IL-1α; the second antigen-binding domain includes a second VL and a second VH, wherein the second VL and the second VH together form a domain capable of specifically binding IL-1β. Furthermore, the second VL includes LCDR1, LCDR2, and LCDR3 contained in the VL shown in any one of SEQ ID NO: 2-6, 10, 154-156; and / or, the second VH includes HCDR1, HCDR2, and HCDR3 contained in the VH shown in SEQ ID NO: 1 or 9.
2. The bispecific antibody of claim 1, wherein, (a) The second VL includes: LCDR1 containing the sequence shown in SEQ ID NO: 16 or 17, LCDR2 containing the sequence shown in SEQ ID NO: 18, and LCDR3 containing the sequence shown in SEQ ID NO: 19; And / or, (b) The second VH includes: HCDR1, which contains the sequence shown in SEQ ID NO: 13; HCDR2, which contains the sequence shown in SEQ ID NO: 14; and HCDR3, which contains the sequence shown in SEQ ID NO:
15. Optionally, the second VL contains an amino acid sequence as shown in any one of SEQ ID NO: 2-6, 10, 154-156, and / or the second VH contains an amino acid sequence as shown in SEQ ID NO: 1 or 9; Preferably, the second VL contains an amino acid sequence as shown in any one of SEQ ID NO: 2-6, 154-156, and / or the second VH contains an amino acid sequence as shown in SEQ ID NO: 1; or, the second VL contains an amino acid sequence as shown in SEQ ID NO: 10, and / or the second VH contains an amino acid sequence as shown in SEQ ID NO:
9.
3. The bispecific antibody of claim 1 or 2, wherein, The first VL includes LCDR1, LCDR2 and LCDR3 contained in the VL shown in SEQ ID NO: 12; and / or, the first VH includes HCDR1, HCDR2 and HCDR3 contained in the VH shown in SEQ ID NO: 11; Optional location: (a) The first VL includes: LCDR1 containing the sequence shown in SEQ ID NO: 23, LCDR2 containing the sequence shown in SEQ ID NO: 24, and LCDR3 containing the sequence shown in SEQ ID NO: 25; And / or, (b) The first VH includes: HCDR1, which contains the sequence shown in SEQ ID NO: 20; HCDR2, which contains the sequence shown in SEQ ID NO: 21; and HCDR3, which contains the sequence shown in SEQ ID NO:
22. Optionally, the first VL contains an amino acid sequence as shown in SEQ ID NO: 12, and / or the first VH contains an amino acid sequence as shown in SEQ ID NO:
11.
4. The bispecific antibody of any one of claims 1-3, further comprising an Fc domain, the Fc domain comprising first and second Fc domain monomers, and each of the first and second Fc domain monomers independently comprising a modification of one or more amino acids, the modification being capable of promoting heterodimerization of the first and second Fc domain monomers.
5. The bispecific antibody of claim 4, wherein, The Fc domain comprises a first Fc domain monomer containing amino acid modifications capable of forming a knot structure (e.g., substitution mutations T366W and / or S354C) and a second Fc domain monomer containing amino acid modifications capable of forming a hole structure (e.g., substitution mutations Y349C, T366S, L368A and / or Y407V), wherein the hole structure can pair with the knot structure to form a heterodimeric Fc domain; Optionally, the first antigen-binding domain and the second antigen-binding domain are each connected to one of the first and second Fc domain monomers; Preferably, the first antigen-binding domain is linked to the first Fc domain monomer, and the second antigen-binding domain is linked to the second Fc domain monomer; or, the first antigen-binding domain is linked to the second Fc domain monomer, and the second antigen-binding domain is linked to the first Fc domain monomer.
6. The bispecific antibody of claim 5, wherein, The first antigen-binding domain and the second antigen-binding domain are Fab; Optionally, the bispecific antibody comprises peptide chain IA, peptide chain IB, peptide chain IC, and peptide chain ID; wherein, peptide chain IA comprises a first VH, a first heavy chain CH1 region, a first hinge region, and a first Fc domain monomer (or a second Fc domain monomer), peptide chain IB comprises a second VH, a second heavy chain CH1 region, a second hinge region, and a second Fc domain monomer (or a first Fc domain monomer), peptide chain IC comprises a first VL and a first light chain constant region, and peptide chain ID comprises a second VL and a second light chain constant region; Preferably, the peptide chain IA comprises, from the N-terminus to the C-terminus, the first VH, the first heavy chain CH1 region, the first hinge region, and the first Fc domain monomer (or the second Fc domain monomer); the peptide chain IB comprises, from the N-terminus to the C-terminus, the second VH, the second heavy chain CH1 region, the second hinge region, and the second Fc domain monomer (or the first Fc domain monomer); the peptide chain IC comprises, from the N-terminus to the C-terminus, the first VL and the first light chain constant region; and the peptide chain ID comprises, from the N-terminus to the C-terminus, the second VL and the second light chain constant region.
7. The bispecific antibody of claim 6, wherein, The adjacent domains of peptide chain IA are optionally connected by or without a connector, the adjacent domains of peptide chain IB are optionally connected by or without a connector, the adjacent domains of peptide chain IC are optionally connected by or without a connector, and / or the adjacent domains of peptide chain ID are optionally connected by or without a connector. Preferably, each of the peptide linkers is independently the same or different peptide linkers (e.g., rigid peptide linkers or flexible peptide linkers); preferably, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
8. The bispecific antibody of claim 5, wherein, The first antigen-binding domain and the second antigen-binding domain are Fab, and the Fab of the first antigen-binding domain or the second antigen-binding domain contains domain exchanges of the form of CrossMab.
9. The bispecific antibody of claim 8, wherein, The Fab of the second antigen-binding domain contains domain exchanges of the form of CrossMab. Optionally, the bispecific antibody comprises peptide chain II-A, peptide chain II-B, peptide chain II-C, and peptide chain II-D; wherein, peptide chain II-A comprises the second VL, a first heavy chain CH1 region, a first hinge region, and a first Fc domain monomer (or a second Fc domain monomer), peptide chain II-B comprises: the first VH, a second heavy chain CH1 region, a second hinge region, and a second Fc domain monomer (or a first Fc domain monomer), peptide chain II-C comprises: the second VH and a first light chain constant region, and peptide chain II-D comprises: the first VL and a second light chain constant region; Preferably, peptide chain II-A comprises, from N-terminus to C-terminus, the second VL, the first heavy chain CH1 region, the first hinge region, and the first Fc domain monomer (or the second Fc domain monomer); peptide chain II-B comprises, from N-terminus to C-terminus, the first VH, the second heavy chain CH1 region, the second hinge region, and the second Fc domain monomer (or the first Fc domain monomer); peptide chain II-C comprises, from N-terminus to C-terminus, the second VH and the first light chain constant region; and peptide chain II-D comprises, from N-terminus to C-terminus, the first VL and the second light chain constant region.
10. The bispecific antibody of claim 8, wherein, The Fab of the first antigen-binding domain contains domain exchanges of the form of CrossMab. Optionally, the bispecific antibody comprises peptide chain II-A, peptide chain II-B, peptide chain II-C, and peptide chain II-D; wherein, peptide chain II-A comprises a second VH, a first heavy chain CH1 region, a first hinge region, and a first Fc domain monomer (or a second Fc domain monomer), peptide chain II-B comprises a first VL, a second heavy chain CH1 region, a second hinge region, and a second Fc domain monomer (or a first Fc domain monomer), peptide chain II-C comprises a second VL and a first light chain constant region, and peptide chain II-D comprises a first VH and a second light chain constant region; Preferably, peptide chain II-A comprises, from N-terminus to C-terminus, the second VH, the first heavy chain CH1 region, the first hinge region, and the first Fc domain monomer (or the second Fc domain monomer); peptide chain II-B comprises, from N-terminus to C-terminus, the first VL, the second heavy chain CH1 region, the second hinge region, and the second Fc domain monomer (or the first Fc domain monomer); peptide chain II-C comprises, from N-terminus to C-terminus, the second VL and the first light chain constant region; and peptide chain II-D comprises, from N-terminus to C-terminus, the first VH and the second light chain constant region.
11. The bispecific antibody of claim 9 or 10, wherein, The adjacent domains of peptide chain II-A are optionally connected by or without a linker, the adjacent domains of peptide chain II-B are optionally connected by or without a linker, the adjacent domains of peptide chain II-C are optionally connected by or without a linker, and / or the adjacent domains of peptide chain II-D are optionally connected by or without a linker. Preferably, each of the peptide linkers is independently the same or different peptide linkers (e.g., rigid peptide linkers or flexible peptide linkers); preferably, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
12. The bispecific antibody according to any one of claims 6-10, wherein, The first Fc domain monomer and / or the second Fc domain monomer are derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4). Preferably, compared to the wild-type Fc domain monomer from which it is derived, the first Fc domain monomer and / or the second Fc domain monomer have altered effector functions (enhanced or reduced or eliminated ADCC, CDC and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity). Optionally, the first Fc domain monomer and / or the second Fc domain monomer are derived from human immunoglobulin IgG1; wherein, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer contains amino acid modifications capable of forming a knob structure (e.g., substitution mutations T366W and / or S354C), and the second Fc domain monomer contains amino acid modifications capable of forming a hole structure (e.g., substitution mutations Y349C, T366S, L368A and / or Y407V). Preferably, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer and / or the second Fc domain monomer each independently further comprise an amino acid mutation selected from: (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii); Preferably, compared to the Fc domain monomer of wild-type human IgG1, the first Fc domain monomer and / or the second Fc domain monomer each independently further comprise an amino acid mutation selected from: (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii); Optionally, one of the first Fc domain monomer and the second Fc domain monomer further comprises the amino acid mutations H435R and / or Y436F; Preferably, the first Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 95, 111, 113, 116, 118, 120, 122, 124, 126, 128, 130-131, 134, and the second Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 94, 110, 112, 114-115, 117, 119, 121, 123, 125, 127, 129, 132, 135; Optionally, the first Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 111, 113, 116, 118, 120, 122, 124, 126, 128, 130-131, 134, and the second Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 110, 112, 114-115, 117, 119, 121, 123, 125, 127, 129, 132, 135; Optionally, the first Fc domain monomer contains the amino acid sequence shown in SEQ ID NO: 95, and the second Fc domain monomer contains the amino acid sequence shown in SEQ ID NO:
94.
13. The bispecific antibody of any one of claims 6-12, comprising one or more features selected from the following: (1) The first light chain constant region and the second light chain constant region are the same or different; (2) The first light chain constant region and the second light chain constant region are each independently selected from the λ or κ light chain constant region of human immunoglobulin; (3) The first light chain constant region and the second light chain constant region each independently contain an amino acid sequence as shown in any one of SEQ ID NO: 138-141, 162; (4) The CH1 region of the first heavy chain and the CH1 region of the second heavy chain are the same or different; (5) The first heavy chain CH1 region and the second heavy chain CH1 region are each independently selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4); (6) The first heavy chain CH1 region and the second heavy chain CH1 region each independently contain an amino acid sequence as shown in SEQ ID NO: 136 or 137; (7) The first hinge area and the second hinge area are the same or different; (8) The first hinge region and the second hinge region are each independently selected from hinge regions derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4); (9) The first hinge region and the second hinge region each independently contain an amino acid sequence as shown in SEQ ID NO:
142.
14. The bispecific antibody of claim 6 or 7, comprising: (1) A peptide chain IA containing the amino acid sequence shown in SEQ ID NO: 66, a peptide chain IB containing the amino acid sequence shown in SEQ ID NO: 67, a peptide chain IC containing the amino acid sequence shown in SEQ ID NO: 63, and / or a peptide chain ID containing the amino acid sequence shown in SEQ ID NO:
68. (2) A peptide chain IA containing the amino acid sequence shown in SEQ ID NO: 69, a peptide chain IB containing the amino acid sequence shown in SEQ ID NO: 70, a peptide chain IC containing the amino acid sequence shown in SEQ ID NO: 63, and / or a peptide chain ID containing the amino acid sequence shown in SEQ ID NO:
68. (3) A peptide chain IA containing the amino acid sequence shown in SEQ ID NO: 71, a peptide chain IB containing the amino acid sequence shown in SEQ ID NO: 67, a peptide chain IC containing the amino acid sequence shown in SEQ ID NO: 63, and / or a peptide chain ID containing the amino acid sequence shown in SEQ ID NO:
72. (4) A peptide chain IA containing the amino acid sequence shown in SEQ ID NO: 73, a peptide chain IB containing the amino acid sequence shown in SEQ ID NO: 74, a peptide chain IC containing the amino acid sequence shown in SEQ ID NO: 63, and / or a peptide chain ID containing the amino acid sequence shown in SEQ ID NO:
72. (5) A peptide chain IA containing the amino acid sequence shown in SEQ ID NO: 75, a peptide chain IB containing the amino acid sequence shown in SEQ ID NO: 76, a peptide chain IC containing the amino acid sequence shown in SEQ ID NO: 63, and / or a peptide chain ID containing the amino acid sequence shown in SEQ ID NO:
72. (6) A peptide chain IA containing the amino acid sequence shown in SEQ ID NO: 77, a peptide chain IB containing the amino acid sequence shown in SEQ ID NO: 78, a peptide chain IC containing the amino acid sequence shown in SEQ ID NO: 63, and / or a peptide chain ID containing the amino acid sequence shown in SEQ ID NO:
72. (7) A peptide chain IA containing the amino acid sequence shown in SEQ ID NO: 79, a peptide chain IB containing the amino acid sequence shown in SEQ ID NO: 80, a peptide chain IC containing the amino acid sequence shown in SEQ ID NO: 63, and / or a peptide chain ID containing the amino acid sequence shown in SEQ ID NO:
72. (8) A peptide chain IA containing the amino acid sequence shown in SEQ ID NO: 81, a peptide chain IB containing the amino acid sequence shown in SEQ ID NO: 70, a peptide chain IC containing the amino acid sequence shown in SEQ ID NO: 63, and / or a peptide chain ID containing the amino acid sequence shown in SEQ ID NO:
72. (9) A peptide chain IA containing the amino acid sequence shown in SEQ ID NO: 82, a peptide chain IB containing the amino acid sequence shown in SEQ ID NO: 83, a peptide chain IC containing the amino acid sequence shown in SEQ ID NO: 63, and / or a peptide chain ID containing the amino acid sequence shown in SEQ ID NO:
72. (10) A peptide chain IA containing the amino acid sequence shown in SEQ ID NO: 84, a peptide chain IB containing the amino acid sequence shown in SEQ ID NO: 85, a peptide chain IC containing the amino acid sequence shown in SEQ ID NO: 63, and / or a peptide chain ID containing the amino acid sequence shown in SEQ ID NO:
72. (11) A peptide chain IA containing the amino acid sequence shown in SEQ ID NO: 86, a peptide chain IB containing the amino acid sequence shown in SEQ ID NO: 87, a peptide chain IC containing the amino acid sequence shown in SEQ ID NO: 63, and / or a peptide chain ID containing the amino acid sequence shown in SEQ ID NO:
72. (12) A peptide chain IA comprising the amino acid sequence shown in SEQ ID NO: 88, a peptide chain IB comprising the amino acid sequence shown in SEQ ID NO: 89, a peptide chain IC comprising the amino acid sequence shown in SEQ ID NO: 63, and / or, a peptide chain ID comprising the amino acid sequence shown in SEQ ID NO: 72; or, (13) A peptide chain IA containing the amino acid sequence shown in SEQ ID NO: 69, a peptide chain IB containing the amino acid sequence shown in SEQ ID NO: 60, a peptide chain IC containing the amino acid sequence shown in SEQ ID NO: 63, and / or a peptide chain ID containing the amino acid sequence shown in SEQ ID NO:
72.
15. The bispecific antibody of any one of claims 9-11, comprising: (a) peptide chain II-A comprising the amino acid sequence shown in SEQ ID NO: 26, peptide chain II-B comprising the amino acid sequence shown in SEQ ID NO: 27, peptide chain II-C comprising the amino acid sequence shown in SEQ ID NO: 28, and / or peptide chain II-D comprising the amino acid sequence shown in SEQ ID NO: 29; or, (b) peptide chain II-A comprising the amino acid sequence shown in SEQ ID NO: 159, peptide chain II-B comprising the amino acid sequence shown in SEQ ID NO: 158, peptide chain II-C comprising the amino acid sequence shown in SEQ ID NO: 161, and / or peptide chain II-D comprising the amino acid sequence shown in SEQ ID NO:
160.
16. The bispecific antibody according to any one of claims 1-3, wherein, The first antigen-binding domain and the second antigen-binding domain are Fab.
17. The bispecific antibody of claim 16, wherein, The Fab of the second antigen-binding domain contains domain exchanges of the form of CrossMab. Optionally, (a) the bispecific antibody comprises peptide chain III-A, peptide chain III-B, and peptide chain III-C; wherein, peptide chain III-A comprises the second VL, a first heavy chain CH1 region, the first VH, a second heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain III-B comprises the second VH and a first light chain constant region; and peptide chain III-C comprises the first VL and a second light chain constant region. Preferably, peptide chain III-A comprises, from the N-terminus to the C-terminus, the second VL, the first heavy chain CH1 region, the first VH, the second heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain III-B comprises, from the N-terminus to the C-terminus, the second VH and a first light chain constant region; and peptide chain III-C comprises, from the N-terminus to the C-terminus, the first VL and a second light chain constant region. (b) The bispecific antibody comprises peptide chain III-A, peptide chain III-B, and peptide chain III-C; wherein, peptide chain III-A comprises a first VH, a first heavy chain CH1 region, a hinge region, an Fc domain monomer, a second VH, and a first light chain constant region; peptide chain III-B comprises a second VL and a second heavy chain CH1 region; and peptide chain III-C comprises a first VL and a second light chain constant region. Preferably, peptide chain III-A comprises, from N-terminus to C-terminus, the first VH, the first heavy chain CH1 region, the hinge region, the Fc domain monomer, the second VH, and the first light chain constant region; peptide chain III-B comprises, from N-terminus to C-terminus, the second VL and the second heavy chain CH1 region; and peptide chain III-C comprises, from N-terminus to C-terminus, the first VL and the second light chain constant region. or, (c) The bispecific antibody comprises peptide chain III-A, peptide chain III-B, and peptide chain III-C; wherein, peptide chain III-A comprises the second VL, the first light chain constant region, the first VH, the first heavy chain CH1 region, the hinge region, and an Fc domain monomer; peptide chain III-B comprises the second VH and the second heavy chain CH1 region; and peptide chain III-C comprises the first VL and the second light chain constant region. Preferably, peptide chain III-A comprises, from the N-terminus to the C-terminus, the second VL, the first light chain constant region, the first VH, the first heavy chain CH1 region, the hinge region, and an Fc domain monomer; peptide chain III-B comprises, from the N-terminus to the C-terminus, the second VH and the second heavy chain CH1 region; and peptide chain III-C comprises, from the N-terminus to the C-terminus, the first VL and the second light chain constant region.
18. The bispecific antibody of claim 16, wherein, The Fab of the first antigen-binding domain contains domain exchanges of the form of CrossMab. Optionally, (a) the bispecific antibody comprises peptide chain III-A, peptide chain III-B, and peptide chain III-C; wherein, peptide chain III-A comprises a first VL, a first heavy chain CH1 region, a second VH, a second heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain III-B comprises: the first VH and a first light chain constant region; and peptide chain III-C comprises: the second VL and a second light chain constant region; preferably, peptide chain III-A comprises, from the N-terminus to the C-terminus, the first VL, the first heavy chain CH1 region, the second VH, the second heavy chain CH1 region, the hinge region, and an Fc domain monomer; peptide chain III-B comprises, from the N-terminus to the C-terminus, the first VH and the first light chain constant region; and peptide chain III-C comprises, from the N-terminus to the C-terminus, the second VL and the second light chain constant region. (b) The bispecific antibody comprises peptide chain III-A, peptide chain III-B, and peptide chain III-C; wherein, peptide chain III-A comprises the second VH, a first heavy chain CH1 region, a hinge region, an Fc domain monomer, the first VH, and a first light chain constant region; peptide chain III-B comprises the first VL and a second heavy chain CH1 region; and peptide chain III-C comprises the second VL and a second light chain constant region. Preferably, peptide chain III-A comprises, from the N-terminus to the C-terminus, the second VH, the first heavy chain CH1 region, the hinge region, the Fc domain monomer, the first VH, and the first light chain constant region; peptide chain III-B comprises, from the N-terminus to the C-terminus, the first VL and the second heavy chain CH1 region; and peptide chain III-C comprises, from the N-terminus to the C-terminus, the second VL and the second light chain constant region. or, (c) The bispecific antibody comprises peptide chain III-A, peptide chain III-B, and peptide chain III-C; wherein, peptide chain III-A comprises a first VL, a first light chain constant region, a second VH, a first heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain III-B comprises the first VH and a second heavy chain CH1 region; and peptide chain III-C comprises the second VL and a second light chain constant region. Preferably, peptide chain III-A comprises, from the N-terminus to the C-terminus, the first VL, the first light chain constant region, the second VH, the first heavy chain CH1 region, the hinge region, and an Fc domain monomer; peptide chain III-B comprises, from the N-terminus to the C-terminus, the first VH and the second heavy chain CH1 region; and peptide chain III-C comprises, from the N-terminus to the C-terminus, the second VL and the second light chain constant region.
19. The bispecific antibody of claim 17 or 18, wherein, The adjacent domains of peptide chain III-A are optionally connected by or without a linker, the adjacent domains of peptide chain III-B are optionally connected by or without a linker, and / or the adjacent domains of peptide chain III-C are optionally connected by or without a linker. Preferably, each of the peptide linkers is independently the same or different peptide linkers (e.g., rigid peptide linkers or flexible peptide linkers); preferably, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
20. The bispecific antibody of any one of claims 17-19, comprising two identical or different peptide chains III-A, two identical or different peptide chains III-B, and two identical or different peptide chains III-C. Preferably, the bispecific antibody comprises two identical peptide chains III-A, two identical peptide chains III-B, and two identical peptide chains III-C.
21. The bispecific antibody according to any one of claims 1-3, wherein, The second antigen-binding domain is scFv, and the first antigen-binding domain is Fab.
22. The bispecific antibody of claim 21, wherein, Intrachain disulfide bonds can be formed between the second VH and the second VL; Preferably, the second VL contains the amino acid sequence shown in SEQ ID NO: 10, and the second VH contains the amino acid sequence shown in SEQ ID NO:
9.
23. The bispecific antibody of claim 21 or 22, wherein, (a) The bispecific antibody comprises peptide chain IV-A and peptide chain IV-B; wherein, peptide chain IV-A comprises: a first VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain IV-B comprises: a first VL, a light chain constant region, a second VH, and a second VL; preferably, peptide chain IV-A comprises, from the N-terminus to the C-terminus, the first VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain IV-B comprises, from the N-terminus to the C-terminus, (i) the first VL, the light chain constant region, the second VH, and the second VL, or (ii) the first VL, the light chain constant region, the second VL, and the second VH; (b) The bispecific antibody comprises peptide chain IV-A and peptide chain IV-B; wherein, peptide chain IV-A comprises: a first VH, a heavy chain CH1 region, a hinge region, an Fc domain monomer, a second VH, and a second VL; peptide chain IV-B comprises: the first VL and a light chain constant region; preferably, peptide chain IV-A comprises, from the N-terminus to the C-terminus, (i) the first VH, a heavy chain CH1 region, a hinge region, an Fc domain monomer, the second VH, and the second VL, or (ii) the first VH, a heavy chain CH1 region, a hinge region, an Fc domain monomer, the second VL, and the second VH; peptide chain IV-B comprises, from the N-terminus to the C-terminus, the first VL and a light chain constant region; or, (c) The bispecific antibody comprises peptide chain IV-A and peptide chain IV-B; wherein, peptide chain IV-A comprises: the first VH, the heavy chain CH1 region, the hinge region, and the Fc domain monomer; peptide chain IV-B comprises: the second VH, the second VL, the first VL, and the light chain constant region; preferably, peptide chain IV-A comprises, from the N-terminus to the C-terminus, the first VH, the heavy chain CH1 region, the hinge region, and the Fc domain monomer; peptide chain IV-B comprises, from the N-terminus to the C-terminus, (i) the second VH, the second VL, the first VL, and the light chain constant region, or (ii) the second VL, the second VH, the first VL, and the light chain constant region.
24. The bispecific antibody according to any one of claims 1-3, wherein, The first antigen-binding domain is scFv, and the second antigen-binding domain is Fab; Choose any location (a) The bispecific antibody comprises peptide chain IV-A and peptide chain IV-B; wherein, peptide chain IV-A comprises: the second VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain IV-B comprises: the second VL, a light chain constant region, the first VH, and the first VL; preferably, peptide chain IV-A comprises, from the N-terminus to the C-terminus, the second VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain IV-B comprises, from the N-terminus to the C-terminus, (i) the second VL, the light chain constant region, the first VH, and the first VL, or (ii) the second VL, the light chain constant region, the first VL, and the first VH; (b) The bispecific antibody comprises peptide chain IV-A and peptide chain IV-B; wherein, peptide chain IV-A comprises: the second VH, a heavy chain CH1 region, a hinge region, an Fc domain monomer, the first VH, and the first VL; peptide chain IV-B comprises: the second VL and a light chain constant region; preferably, peptide chain IV-A comprises, from the N-terminus to the C-terminus, (i) the second VH, a heavy chain CH1 region, a hinge region, an Fc domain monomer, the first VH, and the first VL, or (ii) the second VH, a heavy chain CH1 region, a hinge region, an Fc domain monomer, the first VL, and the first VH; peptide chain IV-B comprises, from the N-terminus to the C-terminus, the second VL and the light chain constant region; or, (c) The bispecific antibody comprises peptide chain IV-A and peptide chain IV-B; wherein, peptide chain IV-A comprises: the second VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain IV-B comprises: the first VH, the first VL, the second VL, and a light chain constant region; preferably, peptide chain IV-A comprises, from the N-terminus to the C-terminus, the second VH, the heavy chain CH1 region, the hinge region, and an Fc domain monomer; peptide chain IV-B comprises, from the N-terminus to the C-terminus, (i) the first VH, the first VL, the second VL, and the light chain constant region, or (ii) the first VL, the first VH, the second VL, and the light chain constant region.
25. The bispecific antibody of claim 23 or 24, wherein, The adjacent domains of peptide chain IV-A are optionally connected by or without a linker, and / or the adjacent domains of peptide chain IV-B are optionally connected by or without a linker. Preferably, each of the peptide linkers is independently the same or different peptide linkers (e.g., rigid peptide linkers or flexible peptide linkers); preferably, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
26. The bispecific antibody of any one of claims 23-25, comprising two identical or different peptide chains IV-A and two identical or different peptide chains IV-B; Preferably, the bispecific antibody comprises two identical peptide chains IV-A and two identical peptide chains IV-B.
27. The bispecific antibody according to any one of claims 17-20 and 23-26, wherein, The Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4). Preferably, the Fc domain monomer is selected from wild-type human immunoglobulin (e.g., IgG1, IgG2, IgG3, or IgG4) Fc domain monomers and their variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity). Optionally, the Fc domain monomer is derived from human immunoglobulin IgG1; Preferably, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from the following: (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii); Preferably, compared to the Fc domain monomer of wild-type human IgG1, the variant comprises an amino acid mutation selected from: (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii); Optionally, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
28. The bispecific antibody of any one of claims 17-20 and 23-27, comprising one or more features selected from the following: (1) The light chain constant region is selected from the λ or κ light chain constant region of human immunoglobulin; (2) The light chain constant region contains an amino acid sequence as shown in any one of SEQ ID NO: 138-141 or 162; (3) The heavy chain CH1 region is selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4); (4) The heavy chain CH1 region contains an amino acid sequence as shown in SEQ ID NO: 136 or 137; (5) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4); (6) The hinge region contains an amino acid sequence as shown in SEQ ID NO:
142.
29. The bispecific antibody of any one of claims 16-20, comprising: (i) a peptide chain III-A comprising the amino acid sequence shown in SEQ ID NO: 32, a peptide chain III-B comprising the amino acid sequence shown in SEQ ID NO: 28, and / or a peptide chain III-C comprising the amino acid sequence shown in SEQ ID NO: 29; (ii) peptide chain III-A comprising the amino acid sequence shown in SEQ ID NO: 33, peptide chain III-B comprising the amino acid sequence shown in SEQ ID NO: 34, and / or peptide chain III-C comprising the amino acid sequence shown in SEQ ID NO: 35; or, (iii) A peptide chain III-A comprising the amino acid sequence shown in SEQ ID NO: 40, a peptide chain III-B comprising the amino acid sequence shown in SEQ ID NO: 41, and / or a peptide chain III-C comprising the amino acid sequence shown in SEQ ID NO:
29.
30. The bispecific antibody of any one of claims 21-26, comprising: (i) a peptide chain IV-A comprising the amino acid sequence shown in SEQ ID NO: 37, and / or a peptide chain IV-B comprising the amino acid sequence shown in SEQ ID NO: 93; (ii) peptide chain IV-A comprising the amino acid sequence shown in SEQ ID NO: 62 or 64, and / or peptide chain IV-B comprising the amino acid sequence shown in SEQ ID NO: 63; or, (iii) A peptide chain IV-A comprising the amino acid sequence shown in SEQ ID NO: 37, and / or a peptide chain IV-B comprising the amino acid sequence shown in SEQ ID NO:
38.
31. The bispecific antibody of any one of claims 1-3, wherein it is in DVD-Ig (Dual Variable Domain-Ig) form; Choose any location (a) The bispecific antibody comprises peptide chain VA and peptide chain VB; wherein, The peptide chain VA comprises: a second VH, a first VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; the peptide chain VB comprises: a second VL, a first VL, and a light chain constant region; preferably, the peptide chain VA comprises, from the N-terminus to the C-terminus, the second VH, the first VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; the peptide chain VB comprises, from the N-terminus to the C-terminus, the second VL, the first VL, and a light chain constant region; or, (b) The bispecific antibody comprises peptide chain VA and peptide chain VB; wherein, peptide chain VA comprises: a first VH, a second VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain VB comprises: a first VL, a second VL, and a light chain constant region; preferably, peptide chain VA comprises, from N-terminus to C-terminus, the first VH, the second VH, a heavy chain CH1 region, a hinge region, and an Fc domain monomer; peptide chain VB comprises, from N-terminus to C-terminus, the first VL, the second VL, and a light chain constant region.
32. The bispecific antibody of claim 31, wherein adjacent domains of the peptide chain VA are optionally linked by or without a linker, and / or adjacent domains of the peptide chain VB are optionally linked by or without a linker. Preferably, each of the peptide linkers is independently the same or different peptide linkers (e.g., rigid peptide linkers or flexible peptide linkers); preferably, each of the peptide linkers independently comprises an amino acid sequence as shown in any one of SEQ ID NO: 143-151.
33. The bispecific antibody of claim 31 or 32, wherein, The Fc domain monomer is derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3, or IgG4). Preferably, the Fc domain monomer is selected from wild-type human immunoglobulin (e.g., IgG1, IgG2, IgG3, or IgG4) Fc domain monomers and their variants; wherein, compared to the wild-type Fc domain monomer from which it is derived, the variant has altered effector functions (enhanced or reduced or eliminated ADCC, CDC, and / or ADCP activities) and / or prolonged half-life (e.g., enhanced FcRn binding activity). Optionally, the Fc domain monomer is derived from human immunoglobulin IgG1; Preferably, the Fc domain monomer is selected from wild-type human immunoglobulin IgG1 Fc domain monomers and their variants; wherein, compared to wild-type human IgG1 Fc domain monomers, the variants contain amino acid mutations selected from the following: (i) D356E and / or L358M, (ii) L234R and / or G236R, (iii) D356E, L358M, L234R and / or G236R, (iv) M428L and / or N434S, (v) M252Y, S254T and / or T256E, (vi) T250Q, M428L and / or N434A, (vii) V308P, M428L and / or N434S, (viii) T307A, M428L and / or N434S, (i (x) T307A, V308P, M428L and / or N434S, (x) M252Y, M428L and / or N434S, (xi) M252Y, V308P and / or N434S, (xii) T250Q, V308P and / or N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii); Preferably, compared to the Fc domain monomer of wild-type human IgG1, the variant comprises an amino acid mutation selected from: (i) D356E and L358M, (ii) L234R and G236R, (iii) D356E, L358M, L234R and G236R, (iv) M428L and N434S, (v) M252Y, S254T and T256E, (vi) T250Q, M428L and N434A, (vii) V308P, M428L and N434S, (viii) T307A, M428L and N434S, (ix) T3 07A, V308P, M428L and N434S, (x) M252Y, M428L and N434S, (xi) M252Y, V308P and N434S, (xii) T250Q, V308P and N434S, (xiii) combinations of (i) and (iv) to (xii), (xiv) combinations of (ii) and (iv) to (xii), (xv) combinations of (iii) and (iv) to (xii); Optionally, the Fc domain monomer comprises an amino acid sequence as shown in any one of SEQ ID NO: 96-109, 133.
34. The bispecific antibody of any one of claims 31-33, comprising one or more features selected from the following: (1) The light chain constant region is selected from the λ or κ light chain constant region of human immunoglobulin; (2) The light chain constant region contains an amino acid sequence as shown in any one of SEQ ID NO: 138-141 or 162; (3) The heavy chain CH1 region is selected from the heavy chain CH1 of human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4); (4) The heavy chain CH1 region contains an amino acid sequence as shown in SEQ ID NO: 136 or 137; (5) The hinge region is selected from the hinge region derived from human immunoglobulins (e.g., IgG1, IgG2, IgG3 or IgG4); (6) The hinge region contains an amino acid sequence as shown in SEQ ID NO:
142.
35. The bispecific antibody of any one of claims 31-34, comprising: (1) A peptide chain VA comprising the amino acid sequence shown in SEQ ID NO: 44, and / or a peptide chain VB comprising the amino acid sequence shown in SEQ ID NO: 45; (2) A peptide chain VA comprising the amino acid sequence shown in SEQ ID NO: 46, and / or a peptide chain VB comprising the amino acid sequence shown in SEQ ID NO: 47; (3) A peptide chain VA comprising the amino acid sequence shown in SEQ ID NO: 48, and / or a peptide chain VB comprising the amino acid sequence shown in SEQ ID NO: 47; (4) A peptide chain VA comprising the amino acid sequence shown in SEQ ID NO: 49, and / or a peptide chain VB comprising the amino acid sequence shown in SEQ ID NO: 47; (5) A peptide chain VA comprising the amino acid sequence shown in SEQ ID NO: 50, and / or a peptide chain VB comprising the amino acid sequence shown in SEQ ID NO: 47; (6) A peptide chain VA comprising the amino acid sequence shown in SEQ ID NO: 51, and / or a peptide chain VB comprising the amino acid sequence shown in SEQ ID NO: 52; (7) A peptide chain VA comprising the amino acid sequence shown in SEQ ID NO: 53, and / or a peptide chain VB comprising the amino acid sequence shown in SEQ ID NO: 47; (8) A peptide chain VA comprising the amino acid sequence shown in SEQ ID NO: 54, and / or a peptide chain VB comprising the amino acid sequence shown in SEQ ID NO: 47; (9) A peptide chain VA comprising the amino acid sequence shown in SEQ ID NO: 55, and / or a peptide chain VB comprising the amino acid sequence shown in SEQ ID NO: 52; (10) A peptide chain VA comprising the amino acid sequence shown in SEQ ID NO: 56, and / or a peptide chain VB comprising the amino acid sequence shown in SEQ ID NO: 47; (11) A peptide chain VA comprising the amino acid sequence shown in SEQ ID NO: 57, and / or a peptide chain VB comprising the amino acid sequence shown in SEQ ID NO: 47; (12) A peptide chain VA comprising the amino acid sequence shown in SEQ ID NO: 163, and / or a peptide chain VB comprising the amino acid sequence shown in SEQ ID NO: 157; or, (13) A peptide chain VA comprising the amino acid sequence shown in SEQ ID NO: 44, and / or a peptide chain VB comprising the amino acid sequence shown in SEQ ID NO:
164.
36. The bispecific antibody of any one of claims 31-35, comprising two identical or different peptide chains VA and two identical or different peptide chains VB; Preferably, the bispecific antibody comprises two identical peptide chains VA and two identical peptide chains VB.
37. An antibody or antigen-binding fragment thereof that specifically binds to IL-1β, comprising: LCDR1, LCDR2 and LCDR3 contained in VL as shown in any one of SEQ ID NO: 3-6, 10; and / or HCDR1, HCDR2 and HCDR3 contained in VH as shown in SEQ ID NO: 1 or 9; Optionally, the antibody or its antigen-binding fragment comprises: (a) LCDR1 containing the sequence shown in SEQ ID NO: 17, LCDR2 containing the sequence shown in SEQ ID NO: 18, and LCDR3 containing the sequence shown in SEQ ID NO: 19; And / or, (b) HCDR1 containing the sequence shown in SEQ ID NO: 13, HCDR2 containing the sequence shown in SEQ ID NO: 14, and HCDR3 containing the sequence shown in SEQ ID NO: 15; Optionally, the antibody or its antigen-binding fragment comprises: VL comprising an amino acid sequence as shown in any one of SEQ ID NO: 3-6, 10, and / or VH comprising an amino acid sequence as shown in SEQ ID NO: 1 or 9; Preferably, the VL contains an amino acid sequence as shown in any one of SEQ ID NO: 3-6, and / or the VH contains an amino acid sequence as shown in SEQ ID NO: 1; or, the VL contains an amino acid sequence as shown in SEQ ID NO: 10, and / or the VH contains an amino acid sequence as shown in SEQ ID NO:
9.
38. An antibody or its antigen-binding fragment that specifically binds to IL-1β, comprising VL and VH, wherein: The N-terminal amino acids 1-3 of the VL have at least one amino acid mutation (e.g., 1, 2, or 3) relative to the amino acid fragment of SYE. Preferably, the amino acid residue fragment at the N-terminus of the VL is EIV, QSV, or SSE; Preferably, the VL comprises LCDR1 with the sequence shown in SEQ ID NO: 16 or 17, LCDR2 with the sequence shown in SEQ ID NO: 18, and LCDR3 with the sequence shown in SEQ ID NO: 19; the VH comprises HCDR1 with the sequence shown in SEQ ID NO: 13, HCDR2 with the sequence shown in SEQ ID NO: 14, and HCDR3 with the sequence shown in SEQ ID NO:
15. Preferably, the antibody or its antigen-binding fragment comprises: VL comprising an amino acid sequence as shown in any one of SEQ ID NO: 4-6, and / or VH comprising an amino acid sequence as shown in SEQ ID NO: 1 or 9; Preferably, the antibody or its antigen-binding fragment comprises: a VL comprising an amino acid sequence as shown in any one of SEQ ID NO: 154-156, and / or a VH comprising an amino acid sequence as shown in SEQ ID NO: 1 or 9.
39. The antibody of claim 37 or 38 or an antigen-binding fragment thereof, said antigen-binding fragment being selected from Fab, Fab', F(ab')2, Fd, Fv, disulfide-linked Fv, scFv, di-scFv, (scFv)2, diabody, and sdAb.
40. Multispecific molecules, which include: (1) The antibody or antigen-binding fragment thereof of any one of claims 37-39; (2) The bispecific antibody of any one of claims 1-36 and an additional antigen-binding domain; or (3) Antibodies that specifically bind to IL-1β or their antigen-binding fragments, wherein: The antibody or antigen-binding fragment comprises LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 16, 18, and 19, and HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 13, 14, and 15; preferably, the antibody or antigen-binding fragment that specifically binds to IL-1β comprises a heavy chain variable region (VH) as shown in SEQ ID NO: 1 and a light chain variable region (VL) as shown in SEQ ID NO:
2. Preferably, the multispecific molecule specifically binds to IL-1β and additionally specifically binds to one or more other targets; Preferably, the multispecific molecule specifically binds to IL-1α and IL-1β, and optionally, additionally specifically binds to one or more other targets; Preferably, the multispecific molecule is a bispecific antibody, or a specific antibody with three, four, five or more specificities.
41. Use of the bispecific antibody of any one of claims 1-36, the antibody of any one of claims 37-39, or the antigen-binding fragment thereof in the preparation of a multispecific molecule; Preferably, the multispecific molecule specifically binds to IL-1β and additionally specifically binds to one or more other targets; Preferably, the multispecific molecule specifically binds to IL-1α and IL-1β, and optionally, additionally specifically binds to one or more other targets; Preferably, the multispecific molecule is a bispecific antibody, or a specific antibody with three, four, five or more specificities.
42. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a bispecific antibody of any one of claims 1-36, or an antibody or antigen-binding fragment thereof of any one of claims 37-39, or a multispecific molecule of claim 40.
43. A vector comprising the isolated nucleic acid molecule of claim 42; Preferably, the vector is a cloning vector or an expression vector.
44. A host cell comprising the isolated nucleic acid molecule of claim 42, or the vector of claim 43.
45. A method for preparing a bispecific antibody of any one of claims 1-36, or an antibody or antigen-binding fragment thereof of any one of claims 37-39, or a multispecific molecule of claim 40, comprising culturing the host cell of claim 44 under conditions allowing expression of the bispecific antibody, antibody or antigen-binding fragment thereof or multispecific molecule thereof, and recovering the bispecific antibody, antibody or antigen-binding fragment thereof or multispecific molecule thereof from the cultured host cell culture.
46. A conjugate comprising a bispecific antibody of any one of claims 1-36, or an antibody or antigen-binding fragment thereof of any one of claims 37-39, or a multispecific molecule of claim 40, and a conjugate portion thereto. Preferably, the coupling portion is selected from therapeutic agents.
47. A pharmaceutical composition comprising a bispecific antibody of any one of claims 1-36, or an antibody or antigen-binding fragment thereof of any one of claims 37-39, or a multispecific molecule of claim 40, or an isolated nucleic acid molecule of claim 42, or a carrier of claim 43, or a host cell of claim 44, or a conjugate of claim 46, and a pharmaceutically acceptable carrier and / or excipient. Preferably, the pharmaceutical composition further comprises an additional pharmaceutically active agent, such as an anti-inflammatory drug or an immunosuppressant; preferably, the bispecific antibody, antibody or its antigen-binding fragment or multispecific molecule is provided with the additional pharmaceutically active agent as a separate component or as a mixed component.
48. Use of the bispecific antibody of any one of claims 1-36, or the antibody or antigen-binding fragment thereof of any one of claims 37-39, or the multispecific molecule of claim 40, or the isolated nucleic acid molecule of claim 42, or the vector of claim 43, or the host cell of claim 44, or the conjugate of claim 46, or the pharmaceutical composition of claim 47 in the preparation of a medicament for use in the prevention and / or treatment of diseases associated with IL-1α and / or IL-1β in a subject; Preferably, the disease is characterized by elevated IL-1α and / or IL-1β expression and / or excessive IL-1α and / or IL-1β activity; Preferably, the disease is an inflammatory disease or an autoimmune disease; Preferably, the disease is selected from: juvenile idiopathic arthritis (JIA), systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease (AOSD), cold pyridine-associated periodic syndrome (CAPS), rheumatoid arthritis (RA), osteoarthritis, gout, gouty arthritis (e.g., acute gouty arthritis), atopic dermatitis, interstitial lung disease (ILD) (e.g., connective tissue disease-associated interstitial lung disease (CTD-ILD), such as rheumatoid arthritis-associated interstitial lung disease (RA-ILD), systemic sclerosis-associated interstitial lung disease (SSc-ILD)), acne, familial Mediterranean fever (FMF), periodic febrile syndrome, neonatal multisystem inflammatory disease, tumor necrosis factor receptor 1-associated periodic febrile syndrome (TRAPS), inflammatory bowel disease, recurrent pericarditis, IL-1 Receptor antagonist deficiency, Mu-Wei syndrome, urticaria, Crohn's disease, ulcerative colitis, multiple sclerosis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis, graft-versus-host disease, hidradenitis suppurativa (HS, such as moderate to severe hidradenitis suppurativa), endometriosis (EM), adenomyosis, endometriosis with adenomyosis, polyarticular juvenile idiopathic arthritis, chronic aseptic osteomyelitis, systemic sclerosis (also known as scleroderma), Behçet's syndrome, uveitis (such as non-infectious uveitis (NIU), infectious uveitis), psoriasis, neurodegenerative diseases, atherosclerosis, metabolic diseases, aging, tumors, thyroid diseases; Preferably, the disease is selected from: endometriosis, adenomyosis, and endometriosis with adenomyosis; the treatment includes non-sequential use of the drug of the present invention (e.g., for adolescents or patients with early-stage endometriosis), or sequential use of the drug of the present invention after hormone therapy (HT) (especially for patients with late-stage endometriosis). Preferably, the disease is selected from: hidradenitis suppurativa (HS, such as moderate to severe hidradenitis suppurativa) and endometriosis; Preferably, the subject is a mammal, such as a human; Preferably, the bispecific antibody, antibody or its antigen-binding fragment, multispecific molecule, isolated nucleic acid molecule, carrier, host cell, conjugate, or pharmaceutical composition is administered in combination with another pharmaceutically active agent, for example, simultaneously, separately, or sequentially. Preferably, the additional pharmaceutically active agent is an anti-inflammatory drug or an immunosuppressant.
49. A polypeptide comprising an Fc domain variant, said Fc domain variant comprising an amino acid mutation selected from the group consisting of, compared to the Fc domain of wild-type human IgG1: (i) T250Q / M428L / N434A, (ii) V308P / M428L / N434S, (iii) T307A / M428L / N434S, (iv) M252Y / M428L / N434S, (v) M252Y / V308P / N434S (vi) T307A / V308P / M428L / N434S, (vii)T250Q / V308P / N434S, The numbering follows the Eu numbering scheme; Optionally, the Fc domain variant further comprises an amino acid mutation selected from any one or a combination of the following: (i) L234R and / or G236R, (ii) D356E and / or L358M (iii) D356E, L358M, L234R and / or G236R.
50. An antibody or antibody fragment comprising the polypeptide of claim 49; Preferably, the antibody is a monoclonal antibody or a multispecific antibody (e.g., a bispecific antibody). Preferably, the bispecific antibody specifically binds to IL-1α and IL-1β; Preferably, the bispecific antibody configuration is DVD-Ig (Dual Variable Domain-Ig) or KIH (Knob-into-Hole).
51. A pharmaceutical composition comprising the polypeptide of claim 49, or the antibody or antibody fragment of claim 50, and a pharmaceutically acceptable carrier and / or excipient.
52. Use of the polypeptide of claim 49, or the antibody or antibody fragment of claim 50, in the preparation of a medicament for use in a subject to prevent and / or treat a disease associated with IL-1α and / or IL-1β; Preferably, the disease is characterized by elevated IL-1α and / or IL-1β expression and / or excessive IL-1α and / or IL-1β activity; Preferably, the disease is an inflammatory disease or an autoimmune disease; Preferably, the disease is selected from: juvenile idiopathic arthritis (JIA), systemic juvenile idiopathic arthritis (sJIA), adult-onset Still's disease (AOSD), cold pyridine-associated periodic syndrome (CAPS), rheumatoid arthritis (RA), osteoarthritis, gout, gouty arthritis (e.g., acute gouty arthritis), atopic dermatitis, interstitial lung disease (ILD) (e.g., connective tissue disease-associated interstitial lung disease (CTD-ILD), such as rheumatoid arthritis-associated interstitial lung disease (RA-ILD), systemic sclerosis-associated interstitial lung disease (SSc-ILD)), acne, familial Mediterranean fever (FMF), periodic fever syndrome, neonatal multisystem inflammatory disease, tumor necrosis factor receptor 1-associated periodic fever syndrome (TRAPS), inflammatory bowel disease, recurrent pericarditis, IL -1 receptor antagonist deficiency, Mu-Wei syndrome, urticaria, Crohn's disease, ulcerative colitis, multiple sclerosis, psoriasis, psoriatic arthritis, systemic lupus erythematosus, ankylosing spondylitis, graft-versus-host disease, hidradenitis suppurativa (HS, such as moderate to severe hidradenitis suppurativa), endometriosis, adenomyosis, endometriosis with adenomyosis, polyarticular juvenile idiopathic arthritis, chronic aseptic osteomyelitis, systemic sclerosis (also known as scleroderma), Behçet's syndrome, uveitis (such as non-infectious uveitis (NIU), infectious uveitis), psoriasis, neurodegenerative diseases, atherosclerosis, metabolic diseases, aging, tumors, thyroid diseases; Preferably, the disease is selected from: endometriosis, adenomyosis, and endometriosis with adenomyosis; the treatment includes non-sequential use of the drug of the present invention (e.g., for adolescents or patients with early-stage endometriosis), or sequential use of the drug of the present invention after hormone therapy (HT) (especially for patients with late-stage endometriosis). Preferably, the disease is selected from: hidradenitis suppurativa (HS, such as moderate to severe hidradenitis suppurativa) and endometriosis; Preferably, the subject is a mammal, such as a human.
53. The application of amino acid mutations selected from the following groups in prolonging the half-life / improving PK or effector function in antibodies, antibody fragments, or fusion proteins: (i) T250Q / M428L / N434A, (ii) V308P / M428L / N434S, (iii) T307A / M428L / N434S, (iv) M252Y / M428L / N434S, (v) M252Y / V308P / N434S (vi) T307A / V308P / M428L / N434S, (vii)T250Q / V308P / N434S, The numbering follows the Eu numbering scheme, and the amino acid mutation is compared to the Fc domain of wild-type human IgG1; Optionally, the amino acid mutation further comprises an amino acid mutation selected from any one or a combination of the following: (i) L234R and / or G236R, (ii) D356E and / or L358M (iii) D356E, L358M, L234R and / or G236R.
Citation Information
Patent Citations
Anti-IL-1beta monoclonal antibody and application thereof
CN106928354A
Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
EP0659766A1
Bivalent, bispecific antibodies
US9266967B2
Heteromultimeric molecules
WO2006028936A2
